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1. Introduction
In  Europe,  cocaine  is  the  second  most  commonly  used  substance  after 
cannabis.  It  is  estimated that  14 million Europeans have used cocaine at 
least once in their lives, an average of 4.3% of the population aged between 
15 and 64 years. 
About  8  million  young  adults  (15-34  years)  are  estimated  to  have  taken 
cocaine at least once, and half of these to have used it over the last year. 
Overall,  cocaine use is  more  prevalent  in  countries  such as  Spain,  Italy, 
Denmark,  Ireland  and  the  United  Kingdom  (EMCDDA,  Statistical  Bulletin 
2011). 
In Italy, cocaine abuse has been detected in over 46% of patients treated by 
Community Addictions Services (Ministry of Health, 2007). 
In  2008,  the  percentage  of  the  Italian  population  aged  15-64  years  who 
reported  having  used  cocaine  at  least  once  rose  to  7% (Department  for 
Antidrug Policies - Report to Parliament 2010).
Epidemiological  data  clearly  show  that  the  identification  of  effective 
interventions for the treatment of cocaine addiction should be prioritised by 
scientific research in the field of addiction. 
Although  recent  studies  carried  out  in  patients  with  cocaine  dependence 
indicated a significant reduction in craving following treatment with ropinirole 
or aripiprazole (Meini et al., 2008; Meini et al., 2011), a review of international 
literature shows that  there are no active  ingredients currently available  to 
have  been  universally  recognised  effective  for  the  treatment  of  cocaine 
dependence (Montoya and Vocci, 2008; Penberthy et al., 2010; Amato et al., 
2011; Pani et al., 2011)  
Moreover, new psycho-social techniques, such as contingency management 
(Kampman, 2010) and cognitive-behavioural oriented psychotherapy (Carroll 
& Onken, 2005; Vocci & Montoya, 2009; Penberthy et al., 2010), have proved 
effective in reducing and eliminating the use of cocaine, and in maintaining 
abstinence from consumption. 
The current literature identifies CBT as a particularly promising therapeutic 
means  also  for  prolonging  significantly  the  periods  of  remission  of  the 
condition  and  for  reducing  the  severity  of  relapse in  patients  with  higher 
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levels  of  craving  and/or  psycho-pathological  compromission  (Carroll  & 
Rounsaville, 1992). 
These techniques have also proved useful in enhancing the effectiveness of 
some medications used in the treatment of conditions related to the use of 
cocaine (Vocci & Montoya, 2009; Sofuoglu M., 2010; Karila et al., 2011). 
In  particular,  many  authors  emphasise  the  usefulness  of  CBT in  helping 
patients  develop specific  strategies  of  contrast  and  avoidance that  would 
reduce the likelihood of resumption of cocaine use (Carroll, 1998; Vocci & 
Montoya,  2009; Carroll  et al  .,  2000; Aharonovich, Nunes, & Hasin, 2003; 
Epstein et al., 2003; Carroll et al., 2004; Rawson et al., 2006; Gonzales et al., 
2006; Penberthy et al., 2010). 
CBT is a short-term intervention, structured and focused on immediate and 
contingent problems faced by patients. 
In  addition  to  enhancing drug therapies  (karila  et  al.,  2011;  M.  Sofuoglu, 
2010), CBT has proven to be flexible and able to adapt to individual patients, 
and also well suited to be integrated in therapeutic programs in outpatient  
setting and, with appropriate measures, in programs carried on in residential 
setting. 
Some authors have already pointed out the usefulness of a group cognitive-
behavioural  approach for  patients who were  diagnosed with  both cocaine 
abuse and dependence (Siqueland et al., 2004; Tzilos et al., 2009, Sanchez 
et al., 2011). 
This study was therefore aimed at validating the group cognitive-behavioural 
therapy for patients with conditions related to the use of cocaine.
2. Cocaine dependence
Cocaine is a powerful stimulant that when abused, typically quickly leads to 
dependence. Cocaine dependence is characterized by the continued use of 
cocaine  despite  significant  substance-related  problems.  Specific  criteria 
include manifesting three or more significant impairments or signs of distress 
which must occur in the same 12 month time period. These include: using 
more  cocaine  or  over  a  longer  period  of  time  than  intended;  having  a 
persistent desire or failed efforts to reduce use; spending a great deal of time 
using, and thus reducing other important social, occupational, or recreational 
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activities to use; using despite physical  or psychological problems that are 
caused or worsened by use; and development of tolerance or withdrawal. The 
fundamental  mechanisms  of  cocaine  dependence  are  not  yet  fully 
understood. Aside from its high risk for abuse and dependency, cocaine use 
poses  health  risks  that  include  respiratory  failure,  cardiovascular 
complications,  gastrointestinal  problems,  mental  disturbances  such  as 
paranoia, and other serious consequences that can lead to death (Gold M., 
2007). In addition to these serious implications, cocaine use has been found 
to have direct negative cognitive effects on the brain, affecting tasks related to 
inhibition,  memory,  concentration,  problemsolving,  learning,  planning, 
attention, and discrimination (Harvey JA, 2004).
Cocaine is a crystalline tropane alkaloid that is extracted from the leaves of 
the  coca  plant.  It  acts  as  a  stimulant  of  the  central  nervous  system, 
specifically as a dopamine reuptake inhibitor, creating a feeling of euphoria 
and increased energy. Cocaine is typically used in one of the following three 
forms: hydrochloride salt, freebase cocaine, crack cocaine. The hydrochloride 
salt is a powder that is administered through snorting or dissolved in water 
and injected intravenously. Freebase cocaine involves chemically treating the 
hydrochloride salt with a base, in order to smoke it, generating a high within 
minutes (Gold M., 2007).
Crack cocaine is processed from freebase cocaine using ammonia and is left 
in a ‘rock’ form. When crack cocaine is smoked, it makes a distinct crackling 
noise,  hence  the  name  (Gold  M.,  2007;  Harvey  JA,  2004),. Two  main 
challenges associated with  treating cocaine dependence include treatment 
retention and relapse (O’Brien CP, 2005). The primary addictive triggers that 
instigate  drug  use  are  psychological  or  physiological  stresses,  social  and 
environmental cues, and the presence of cocaine itself (DeVries et al., 2001). 
Cocaine  directly  affects  neurological  function,  creating  a  conditioned 
response for use and pleasure, a pattern that is difficult to break (Filmore and 
Rush, 2002; Kilts et al., 2001).
In  cocaine-dependent  individuals,  many  areas  of  the  brain  are  impacted, 
making  effective  treatment  and  patient  retention  difficult  (Martinez  et  al., 
2004). One of the areas affected by cocaine use is the frontal  lobe of the 
brain. The frontal lobe is associated with emotion, problem solving, memory, 
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judgment, impulse control, and spontaneity (Filmore and Rush, 2002; Kilts et 
al., 2001;Stalnaker et al, 2007).
Cocaine use leads to hypofrontality, or reduced activity in the frontal portions 
of the brain, and this negatively impacts effective decision making and lowers 
motivation for goal directed activities (Dackis et al., 2008).
2.1. Cocaine and the Dependence Pathway
Brain pathways involved in creating a stimulus-reward response for cocaine 
are  natural  pathways  that  encourage  certain  appetitive  and  pleasurable 
behaviors  such as eating and sex (Gold  M.,  2007).  In  humans and other 
animals, these pathways promote engagement in and repetition of behaviors 
that  are  rewarding.  The  stimulus-reward  response  creates  pleasurable 
feelings that serve as positive reinforcement for the behavior, leading to the 
likelihood that a given behavior will be repeated in an attempt to recreate the 
feelings.  Psychomotor  stimulants,  such  as  cocaine,  similarly  healthier 
behaviors,  such as sex and eating, cause the release of dopamine in the 
nucleus accumbens, creating feelings of pleasure (Cleck et al.,  2008) that 
serve to reward drug-taking behavior.
When cocaine is administered to the body it  enters all  parts  of  the brain,  
binding  to  specific  sites  involved  in  reward  and  dependence:  the  ventral 
tegmental area (VTA), nucleus accumbens, and caudate nucleus (Harvey JA, 
2004). This activated pathway is known as the mesolimbic dopamine reward 
pathway (Cleck and Blendy, 2008). The VTA is connected to both the nucleus 
accumbens and the prefrontal cortex by the ‘pleasure pathway’  and sends 
information to these cooperating structures via its neurons (Harvey JA, 2004). 
The neurons of the VTA contain the neurotransmitter dopamine, which, when 
activated by a rewarding stimulus, is released in the nucleus accumbens and 
the prefrontal  cortex (Harvey JA, 2004;  Schoenbaum and Shaham, 2007). 
Once inside the synaptic cleft,  dopamine binds to the dopamine receptors, 
and then is released for reuptake, promoting pleasurable sensations (Harvey 
JA, 2004).
Animal  research suggest  that  cocaine may act  as a dopamine transporter 
antagonist,  blocking  dopamine  from  binding  at  the  transporter  site,  and 
preventing the reuptake of dopamine (Harvey JA, 2004). This function floods 
7
the  synapse  with  dopamine  and  creates  an  extended  state  of  euphoria, 
eventually  leading  to  dependence  (Harvey  JA,  2004;  Kilts  et  al.,  2001; 
Martinez et al., 2007). However, withlong-term use of cocaine, the number of  
receptors varies depending on the area of the brain as the nervous system 
tries to adapt to this high level of dopamine. In rats, the density of dopamine 
receptor  D1 in  frontal  cortex  is  either  unchanged or  slightly  increased 20 
minutes after  the last  cocaine daily injection,  but  was decreased 2 weeks 
later. D1 sites in striatum are decreased both immediately and 2 weeksafter 
the  injection  regimen.  Decreases  in  D1  binding  site  density  in  nucleus 
accumbens  were  observed  only  immediately  after  the  last  injection.  In 
contrast to these effects on D1 binding sites, D2 binding sites were decreased 
in striatum and frontal  cortex and increased in the nucleus accumbens 20 
minutes after repeated cocaine, but were unaffected 2 weeks after repeated 
cocaine. Furthermore, cocaine caused opposite, transient effects on D1 and 
D2 site density in nucleus accumbens (Kleven et al., 1990). Consequently,  
the brain becomes more sensitive to and reliant on the excess presence of 
dopamine, creating both a physical and psychological dependence that leads 
to an intense desire to use cocaine again to attempt to re-experience the first  
initial “high” (Harvey JA, 2004).
Over time, the same amount of cocaine has a reduced effect. As a result, in 
many  cases,  the  user  will  only  feel  good,  or  “normal”  by  using  cocaine 
(Penberthy and Wartella, 2007).
After cocaine dependence has developed, users often experience an inability 
to feel pleasure without cocaine, leading to depression, increases in impulsive 
behavior, and further drug use (Penberthy and Wartella, 2007).
Using positron emission tomography (PET) scans in humans, Volkow found 
that  detoxified cocaine abusers have fewer  dopamine D2 receptors in the 
basal  ganglia  than normal  controls  (Volkow et  al.,  1997).  This  deficit  was 
long-lasting and persisted even as long as four months after detoxification.
These  dopamine  D2  receptors  low  densities  were  alsoassociated  with 
decreased metabolism in  the  orbitofrontal  cortex,  an  area associated  with 
obsessive-compulsive disorder (OCD). It is tempting to conclude from these 
results that cocaine use may affect the brain in a way that makesdrug taking a 
compulsive behavior. One of the long-term effects of repeated cocaine use 
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may be a state of relative dopamine dysfunction. This dopaminergic activity 
downregulation may help explain the anhedonia reported by cocaine users, 
and the fact that they use cocaine to reverse the negative emotional state in 
an attempt to go back to normal mood and functioning.
2.2. Other Areas of the Brain Impacted
Brain  scans  and  medical  studies  show that  certain  areas  of  the  brain  of 
cocaine dependent individuals are less active while other parts of the brain 
exhibit heightened activity (Kilts et al., 2001).
Furthermore,  PET  scans  in  cocaine  dependent  patients  have  indicated 
activation in the limbic and frontal structures of the brain that is dissimilar from 
those of control subjects (Kilts et al., 2001).
Specific  structures  involved  in  the  excitation  include  the  amygdala,  which 
functions in stimulus-reward associations and emotion, the sub callosal gyrus 
and nucleus accumbens, which are associated with incentive motivation and 
pleasure, and which helps to explain the underlying reinforcing effects of drug 
use.  The  anterior  cingulate  gyrus,  which  is  associated  with  anticipation, 
emotion, learning, memory, and controlling action, also exhibits similar effects 
(Kilts et al., 2001; Schoenbaum and Shaham, 2007; Grant et al., 1996).
Another  major  brain  system that  has demonstrated differences in  cocaine 
dependent individuals is the white  matter of the brain, composed of myelin, 
which  increases  impulse  speed  and  through  which  messages  and  nerve 
impulses pass. In cocaine users, the white matter content has been found to 
be lower than in non-cocaine users (Moeller et al., 2005). The loss of this 
matter suggests that the users’ myelin production has decreased, a condition 
called  demyelination,  and  which  can  lead  to  speech  impairment,  memory 
loss, and decreased motor function (Moeller et al., 2005) .
As a dopamine transporter antagonist, cocaine eliminates the natural effects 
of  dopamine  reuptake,  therefore  inducing  a  state  of  dopaminergic  down 
regulation.  In  twenty-four  cocaine-dependent  participants  and  an  equal 
number of matched healthy subjects,  cocaine dependence was associated 
with  a marked reduction in amphetamine-induced dopamine release in the 
striatum. Blunted dopamine transmission in the ventral striatum and anterior 
caudate was predictive of the choice for cocaine over money.  This altered 
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dopaminergic  function  may play  a  critical  role  in  relapse  (Martinez  et  al., 
2007). The decrease in dopamine function in these previously identified brain 
regions could explain the difficulty that people addicted to cocaine have in 
altering their habitual behavior. It may also explain their inability, at times, to 
respond positively to therapy and different rewards to encourage healthier 
behaviors.  In  cocaine  dependent  patients,  the  over  stimulation  of  certain 
neural  circuits  may  impair  inhibitory  functions,  which  can  then  lead  to 
lessened behavioral control and result in continued drug use, despite efforts 
towards abstinence (Filmore and Rush, 2002).
Brains scans of both cocaine dependent and control subjects show activity in 
the dorsal striatum, involved in the selection and initiation of actions, reflexes 
and habits, as well as reward and cue association (Volkow et al., 2006). This 
stimulation  is  implicated  in  habit  formation  as  well  as  in  the  subjective 
experience of “desire”. Identical neural activation is shown in images when 
both  subjects  are  prompted  with  images  of  food.  In  cocaine-dependent 
individuals, the same activation is evident when subjects are shown images of 
cocaine,  demonstrating  that  the  same  neural  processes  are  activated  for 
natural rewards necessary for survival and for the drug of abuse (Volkow et 
al., 2006).
2.3. Relapse and retention
Cocaine  is  a  highly  addictive  substance  that  creates  a  high  level  of 
dependence  and  physical  harm  (Nutt  et  al.,  2007).  Cocaine  users  often 
increase  their  dose  in  order  to  intensify  and  prolong  the  euphoric  effects 
created by cocaine (Penberthy and Wartella, 2007). Herein lays the danger of 
cocaine: because of its intense psychological effects the user may pursue a 
more intense and enduring ‘high’ by increasing their dosage. This increased 
dosage of cocaine ultimately may accommodate this excess by affecting the 
brain’s dopaminergic function in key areas (Harvey JA, 2004; Penberthy and 
Wartella, 2007).
The psychological and social aspects of cocaine dependence complicate its 
treatment, leading to low rates of patient retention in treatment programs as 
well as high rates of patient relapse (Sinha et al., 2006). The main obstacles 
to retention include the often chaotic lifestyle and environment in which the 
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cocaine  dependent  patient  lives,  lack  of  motivation  to  change,  and 
compromised  cognitive  functioning  of  the  patients,  which  affects  their 
participation in treatment, andincreases rates of relapse (O’Brien CP, 2005). 
The  three  major  stimuli  which  trigger  relapse  are  psychosocial  stress, 
environmental and social cues, and the presence of the drug itself (DeVries et 
al., 2001). These triggers are hypothesized to promote pleasant or rewarding 
thoughts of use and promote permissive thoughts that encourage or allow use 
of  the  drug.  In  addition,  confounding  issues  associated  with  cocaine 
dependence  include  cognitive  and  behavioral  impairment,  and  co-morbid 
psychiatric  disorders  such  as  alcohol  and  drug  abuse  and  dependence, 
depression,  Attention  Deficit  Hyperactive  Disorder  (ADHD),  Obsessive 
Compulsive  Disorder  (OCD),  and  Antisocial  Personality  Disorder  (ASPD) 
(Filmore and Rush, 2002). Data show that cocaine abusers display difficulty 
adapting their behaviors to environmental changes.
They  exhibit  difficulty  in  functioning  in  new  and  different  situations  or 
interacting  with  new  people,  and  typically  avoid  deviating  from  their 
established routines (Filmore and Rush, 2002). Studies show that early onset 
cocaine users exhibit impaired social skills (Messina et al., 2003), which may 
be  due  to  their  developing  cocaine-seeking  behavior,  or  the  effect  of  the 
interaction of the drug with the frontal lobe in the brain, which is associated 
with emotional regulation.
Further contributing to difficulties with treatment retention and relapse is the 
underlying issue of cocaine’s prevailing effects on the brain. Long-term use is 
associated  with  deficits  in  performance  of  neuropsychological  tasks  in 
memory,  attention,  learning,  problem-solving,  perceptual  motor  speed. 
Neuroimaging studies have shown impairments of the frontal lobe function, 
which serves to regulate behavioral control via suppression or termination of 
environmentally-triggered responses. 
In addition, data suggest repeated dopaminergenic activation by cocaine in 
neural  circuits  eventually impairs inhibitory functions,  resulting in  a  loss of 
control  over  behavioral  impulses,  including  the  impulse  to  continue  using 
cocaine (Filmore and Rush, 2002).
Kelley  found  cognitive  impairment  pertaining  to  visuospatial  tasks  and 
concentration developed in cocainedependent individuals under going acute 
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withdrawal at 72 hours and up to 14 to 18 days (Kelley et al., 2005). These 
individuals recorded poor performance in tasks of cognitive flexibility,  tasks 
which are mediated by the anterior cingulate gyrus and the dorsal striatum in 
the frontal part of the brain which, as was mentioned earlier, are activated by 
cocaine administration (Kilts et al., 2001). It appears that the neural circuitry 
activated by cocaine use becomes somewhat deactivated in the absence of 
the drug. Consequently, this mechanism contributes to abstinence becoming 
a  major  obstacle  for  addicts  to  overcome,  as  they are  forced  to  re-learn 
normal cognitive tasks in the absence of cocaine, and re-wire their neural 
pathways to function normally without cocaine (Kilts et al., 2001; Martinez et 
al., 2007; Moeller et al., 2005).
In  research  using  cocaine-treated  rats,  Stalnaker  attributed  deficits  in 
decision-making  and  trouble  with  reversal-learning  or  unlearning  certain 
behaviors to cueselective neurons in the basolateral amygdale (Stalnaker et 
al., 2007a). The rats displayed a failure to change cue preference [choosing 
cocaine over  food for  reward]  during  reversal  learning,  which  researchers 
attributed to persistent  encoding of outdated associative information in the 
basolateral  amygdala  (Stalnaker  et  al.,  2007a;  Stalnaker  et  al.,  2007b). 
Cocaine  exposure  and  associated  cues  affect  behavioral  flexibility  (e.g. 
learning novel responses) related to the basolateral membrane and continues 
to affect behavior even in the face of negative consequences, contributing to 
relapse and compulsive drug-seeking (DeVries et al., 2001; Stalnaker et al., 
2007a; Stalnaker et al., 2007b)
Stress  and  drug  cue  exposure  increase  perceived  arousal  and  cocaine 
cravings,  leading to  relapse (DeVries  et  al.,  2001;  Sinha et  al.,  2006).  In 
attempting  to  abstain  from  cocaine  use,  individuals  frequently  experience 
emotional,  physical,  and  social  stresses  (Penberthy  and  Wartella,  2007). 
These stressors can arise from their social home environment, if people they 
live with use or if they live in close proximity to where they can obtain cocaine.
Furthermore, removing cocaine from the brain exerts a physical stress on the 
neural circuitry,  as it has become reliant on cocaine to function normally to 
offset the dopaminergic dysfunction (Sinha et al., 2006).  Cocaine exerts its 
primary  rewarding  effects  on  the  stress-dependent  mesolimbic  dopamine 
reward pathway.
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Studies show a positive correlation between stress and drug craving, implying 
activation of the reward pathways following exposure to stressors as well as 
triggers and cues associated with cocaine use (Cleck and Blendy, 2008).
Sinha found stress-induced cocaine cravings and action of the hypothalamic-
pituitary adrenal (HPA) axis, responsible for stress and craving, are positively 
associated  with  cocaine  relapse  (Sinha  et  al.,  2006).  Data  show a  direct 
correlation between the elevation of the stress hormones and the average 
cocaine use per occasion (Sinha et al., 2006).
Cocaine administration, or the decision to use cocaine, has been associated 
with priming effects, or triggers that initiate the desire to use (Kilts et al., 2001; 
Stalnaker et al., 2007b; Mahoney et al., 2007). Drug cues can be triggered by 
internal  or  external  experiences,  activating  the  craving-related  network  of 
brain  structures  such  as  the  amygdala,  nucleus  accumbens,  and  anterior 
cingulate gyrus involved in stimulus-reward (Kilts et al., 2001). Priming effects 
from cues can be moderated by the frequency and duration of cocaine use, 
environmental factors, and drug availability (Mahoney et al., 2007).
Another  possible  factor  related  to  cocaine  dependence  is  the  striatal 
dopamine receptor  availability  in  the  brain.  With  chronic  cocaine  use,  the 
receptor availability may decrease, thus prompting a desire for the drug in the 
absence of the dopamine release achieved by natural rewards (Martinez et 
al., 2004).
3. Pharmacoterapies
3.1.Topiramate
Formulated as an anticonvulsant to treat patients with epilepsy,  topiramate 
has been found to be superior to placebo in treating both early and late onset 
alcoholics (Johnson et al., 2007), and has shown promise in treating medical 
issues ranging from migraines, diabetic neuropathic pain, mood and anxiety 
disorders, eating disorders and obesity (Johnson et al., 2007; Johnson BA, 
2004; Youric and Faiman, 1989). Topiramate is a sulphamate fructopyranose 
derivative,  thought  to  antagonize  a  drug’s  rewarding  effects  by  inhibiting 
mesocorticolimbic  dopamine  release  via  the  gamma  aminobutyric  acid 
(GABA) activity and inhibition of glutamate function after drug intake (Johnson 
BA,  2004;  Johnson  et  al.,  2003).  Through  this  activity,  topiramate  may 
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decrease  extracellular  release  of  dopamine  in  the  VTA  projecting  to  the 
nucleus accumbens. This action may mediate drug-seeking behaviors and 
craving by reducing the rewarding effects associated with drug use (Johnson 
et a l., 2007; Johnson BA, 2004).
Promising topiramate doses range from 25mg to 300mg (Reis et al., 2008; 
Johnson et al.,  2007).  However as the dose increases beyond 100mg per 
day,  so  does  the  occurrence  of  adverse  events.  Most  common  adverse 
events  include:  dizziness,  parasthesia,  psychomotor  slowing,  memory  and 
concentration impairment and weight loss. With a half life of 21 to 23 hours 
and at 80% bioavailability, a single daily dose of topiramate is sufficient for 
treatment  and  remain  active  in  the  blood  to  enact  its  anticraving  effects 
(Johnson  BA,  2004).  Results  from  a  12-week  outpatient  trial  for  cocaine 
dependent individuals, using varied, high and low doses of topiramate ranging 
from 25 to 100 mg daily, show a 57% compliance rate and 25% of the sample 
reported a significant decrease in craving intensity and duration (Reis et al., 
2008).
Two major limitations to this study is that it is an open trial without placebo or 
control group and the small sample size (N= 28 males).
Researchers  at  the  University  of  Pennsylvania  School  of  Medicine  tested 
topiramate 200mg daily against placebo in 40 chronic, crack-cocaine-smoking 
outpatients for 13 weeks (Kampman et al., 2004). In nearly every week of the 
study, compared to the placebo groups, more patients in the topiramate group 
refrained from cocaine use and more exhibited 3 or more continuous weeks 
of abstinence (Kampman et al., 2004). Larger placebo controlled randomized 
trials testing varied doses of topiramate are needed to learn more about the 
effects of topiramate for the treatment of cocaine dependence.
3.2  Disulfiram
Disulfiram  is  a  drug  that  inhibits  aldehyde  dehydrogenase,  an  enzyme 
necessary in alcohol metabolism to convert acetaldehyde to acetate, and has 
been approved for the treatment of alcoholism (Johnson BA, 2004; Brien and 
Loomis, 1983; Haley TJ, 1979) . Haley showed that alcohol use in conjunction 
with disulfiram resulted in an adverse physical reaction due to acetaldehyde 
accumulation in blood with symptoms including hypotension, flushing, nausea 
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and vomiting that  discourage future use (Johnson BA, 2004;  Baker  et  al.,  
2006).  In  humans,  disulfiram  also  inhibits  plasma  and  microsomal 
carboxylesterases and plasma cholinesterase (McCance-Katz  et  al.,  1993; 
McCance-Katz  et  al.,  1998)  that  inactivate  cocaine  systemically  thereby 
increasing  blood  levels  of  cocaine  (Haile  et  al.,  2009)  without  any 
cardiovascular  toxicity.  Another  important  role  is  that  disulfiram  chelates 
copper, and since copper is essential in the function of the dopamine beta-
hydroxylase enzyme, disulfiram inhibits the conversion
of  dopamine  to  norepinephrine  (Haile  et  al.,  2009).  Dopamine 
betahydroxylase inhibition by disulfiram leads to decreases in peripheral and 
central  norepinephrine  and  increases  in  dopamine  levels.  This  effect  is 
believed to  contribute to  disulfiram’s efficacy in  treating cocaine addiction. 
Disulfiram has also  been studied  as  a  treatment  for cocaine dependence 
(Baker et al., 2006). In a randomized, double-blind, placebo-controlled study 
examining the interaction of disulfiram 62.5 or 250 mg/day with intravenous 
cocaine, disulfiram  was  found  to  decrease  self-reported  'high'  and 'rush' 
associated  with  cocaine  use.  The  highest  dose  of disulfiram had  a  more 
significant reduction on the subjective effects of cocaine with,  the average 
cocaine ‘rush’ felt with a 62.5mg or 250mg dose of disulfiram decreased 60% 
and 46%, respectively (Backer et al., 2006).
 In a double blind randomized outpatient clinical trial conducted by Carroll et 
al.,  121  cocaine  dependent  patients were  randomized  to  either  disulfiram 
250mg daily  or  placebo plus  weekly  therapy (either  CBT or  Interpersonal 
Therapy; IPT) for 12 weeks (Carroll et al., 1998). Participants taking disulfiram 
demonstrated greater reductions in cocaine use than those taking placebo or 
receiving IPT, with results that were equivalent to CBT.  Disulfiram was also 
associated with better patient retention and a longer duration of abstinence 
from drug use (Carroll et al., 1998).
Some studies with disulfiram in cocaine dependent population showed that 
higher doses (up to 3 gm loading dose, and up to 1 gm/day for maintenance) 
were associated with paranoid psychosis in some patients (Martensen-Larsen 
O., 1951), therefore limiting its use in certain patients. Overall, there is good 
evidence  indicating  that  disulfiram  shows  significant  promise  as  a 
pharmacological  treatment  for  cocaine  dependence.  Future  studies  are 
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needed to clarify the mechanisms involved,  and the contributions of other 
factors that may impact treatment response.
3.3. Ondansetron
Post-synaptic  5-HT3  receptors  are  located  densely  on  the  terminals  of 
corticomesolimbic  dopamine  containing  neurons,  where  they  promote  DA 
release  (Klipatrick  et  al.,  1987;  Oxford  et  al.,  1992).  A  primary  effect  of 
ondansetron a 5-HT3 antagonist is to decrease dopamine release, especially 
under suprabasal conditions in these regions. In a human laboratory study of 
12 cocainedependent individuals, ondansetron pretreatment was associated 
with  a  significant  dose-dependent  decrease  in cocaine-induced  positive 
subjective  effects  associated  with its  abuse  liability  and  reinforcement 
(Jasinski  et  al.,  1990).  Under  a  NIDA  directed and  -sponsored  contract, 
Johnson BA et al. (2006) conducted a preliminary double-blind, randomized, 
doseranging clinical  trial  to  examine  for  a  therapeutic  signal, testing  the 
efficacy of ondansetron (0.25, 1.0, and 4.0 mg twice daily)  vs  placebo as a 
treatment  for  cocaine dependence  among  63  male  and  female  cocaine-
dependent individuals. Ondansetron (4 mg twice daily) was significantly more 
efficacious than placebo at increasing the weekly proportion of cocaine-free 
urine specimens (p = 0.02) and was marginally significantly more efficacious 
at decreasing the urine benzoylecgonine concentration (p = 0.07) (Johnson et 
al.,  2006).  Important  limitations  of  the  study  however, include  the  small 
sample size and a higher than expected overall dropout rates.
3.4. Baclofen
Baclofen is a GABA B receptor agonist used to reduce muscle spasticity in 
different  neurological  diseases.  It  is  believed to  modulate cocaine-induced 
dopamine release in the nucleus accumbens (Fadda et al., 2003). In animal 
studies  baclofen  was  found  to  reduce  cocaine  self  administration, 
reinstatement, and cocaine seeking behaviors in rats suggesting its potential 
utility as a medication for treatment of cocaine addiction (Roberts DC, 2005). 
In humans, an open label study found that baclofen 20 taken three times daily 
significantly reduced cocaine craving in cocaine-dependent subjects (Ling et 
al., 1998). However, this trial had a sample size of 10 and did not have a 
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placebo  arm.  A  randomized,  double-blind  clinical  trial  involving  70 
cocainedependent  treated  with  baclofen  60  mg/d  or  placebo  found  no 
statistically significant effect for baclofen over placebo on measures such as 
treatment effectiveness and percent negative urines. A secondary analysis of 
the same data found that baclofen significantly reduced cocaine use in the 
subgroup of patients with the heaviest cocaine use only (Shoptaw S., 2000). 
In  a  human  laboratory  study,  baclofen  60  mg/d  reduced  cocaine  self-
administration in non-treatment seeking cocaine dependent volunteers who 
were non-opioid dependent (Haney et al., 2006).
3.5.Modafinil
Modafinil,  a  functional  stimulant,  is  FDA  approved  for  the  treatment  of 
narcolepsy  and  idiopathic  hypersomnia.  The  mechanisms  underlying 
modafinil’s therapeutic actions remain unknown. It is believed to occupy both 
the dopamine and norepinephrine transporters consistent with a stimulantlike 
effect  but  its  affinity  to  these  transporters  is  well  below  that  of  the 
antidepressant  buproprion  (Madras  et  al.,  2006;  O’Brien  et  al.,  2006).  In 
addition,  modafinil  appears  to  increase  release  of  the  excitatory 
neurotransmitter  glutamate,  and  decrease  the  inhibitory  neurotransmitter 
GABA (Ballon and Feifel, 2006). Modafinil is usually well tolerated, although 
up to  3% of  patients  on  modafinil  experienced cardiovascular  side-effects 
such as hypertension, tachycardia, and palpitations. Because of its stimulant-
like  activity,  modafinil  was  suggested  and  later  tested  as  a  treatment  for 
cocaine dependence. It was believed to diminish not only the symptoms of 
cocaine  withdrawal,  but  also  act  as  a  “substitution  treatment”  for  cocaine 
(Dackis et al., 2003). In animal studies, modafinil was found to have a weak 
cocainelike reinforcement effect (Deroche-Gamonet et al., 2002). In humans, 
modafinil  did  not appear  to  produce  euphoria  or  evoke  cocaine  craving 
(O’Brien et al., 2006; Ballon and Feifel, 2006 suggesting that it has low abuse 
potential  and  that  is  not  an  amphetamine  like  agent  (Jasinski  DR,  2000; 
Jasinski and Kovacevic-Ristanovic, 2000).
 Dackis et al. (2005) conducted the first randomized, doubleblind clinical trial 
testing the efficacy of modafinil 400 mg daily  vs placebo in conjunction with 
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CBT in  62  cocainedependent  patients  for  8  weeks  (Dackis  et  al.,  2005). 
Patients in the active group had significantly less cocaine use compared to 
their  placebo  counterpart.  In  a  multi-site,  controlled  clinical  trial  of  210 
cocaine-dependent patients who received either modafinil (200 mg/d or 400 
mg/d) or placebo, Modafinil significantly reduced cocaine use but only in the 
subgroup of patients without alcohol dependence (Elkashef and Vocci, 2007). 
Additional  clinical  trials  are  needed  to  evaluate  the  best  clinical  role  of 
modafinil for the treatment of cocaine dependence.
3.6. Immunotherapy
Immunotherapy  is  a  relatively  new  approach  to  treating  addictions,  in 
particular cocaine addiction. TA-CD (Celtic Pharma, Hamilton, Bermuda) is a 
cocaine derivative (succinylnorcocaine) coupled to recombinant cholera toxin 
B that when injected can bind to the circulating cocaine and produce cocaine-
specific antibodies. Cocaine is a small molecule that enters the brain, where it 
elicits its pleasurable effects and addictive properties. The cocaine-antibody 
complex is a large molecule that does not enter the brain and thus impedes 
cocaine's  access to  the  brain.  In  rats,  the  anticocaine antibodies  produce 
extinction  of  cocaine  self-administration  (Kantak  et  al.,  2000).  Studies  in 
humans have shown that TA-CD has good immunogenicity for  cocaine, is 
medically  safe,  and  may  be  beneficial  for  treating  cocaine  dependence 
(Kosten et al., 2002; Martell et al., 2005). 
The vaccine is shown to inhibit the cocaine ‘high’ through antibodies binding 
to cocaine in the circulation and inhibiting entry to the brain (Fox BS, 1997; 
Martell et al., 2005). However, it does not stop drug cravings (Carroll et al.,  
2009).
In addition, recent findings suggest that only those subjects who attain high (> 
43 ug/L) IgG anticocaine antibody levels benefited from significantly reduced 
cocaine use.  Unfortunately,  only 38% of  the vaccinated subjects achieved 
such high IgG levels in this study.
The  intent  of  the  vaccine  is  to  immunize  motivated  patients  as  part  of  a 
comprehensive  recovery  program  and  to  inhibit  the  reinforcing  activity  of 
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cocaine and decrease the likelihood of relapse (Fox BS, 1997; Martell et al.,  
2005).
3.7. Other Medications
Other medications that interact with GABA- or glutamate-mediated neuronal 
systems  have  been  tried  as  potential  treatment  for  cocaine  dependence. 
While there is preclinical evidence that acamprosate can inhibit conditioned 
place  preference  to  cocaine (McGeehan  and Olive,  2003)  and  attenuates 
both  drug  and cue-induced  reinstatement  of  cocaine-seeking  behaviour 
(Bowers  et  al.,  2007) there  is  to  date,  no  clinical  trial  testing  its  utility  in 
treating humans with cocaine dependence. In humans, several clinical trials 
have been conducted using carbamazepine to treat cocaine dependence. A 
metaanalysis  of  455  individuals  enrolled  in  five  different  clinical  trials 
conducted by the Cochrane Database of Systematic Reviews concluded that 
there was no evidence supporting a positive effect of carbamazepine in the 
treatment of cocaine dependence (Johnson BA, 2005; Lima et al., 2000).
Gabapentin  is  another  gabanergic  drug  used  to  treat  both  epilepsy  and 
neuropathic  pain.  Its  exact  pharmacological  mechanism  remains  unclear. 
Gabapentin has showed some promising results in an open-label study and 
case series suggesting that it might have utility in the treatment of cocaine 
dependence  (Raby  and  Coomaraswamy,  2004;  Myrick  et  al.,  2001). 
Randomized, placebo controlled, double-blind studies are needed to test its 
efficacy.
There are encouraging preclinical data that support the utility of vigabatrin as 
a  treatment  agent  for  cocaine  dependence.  Vigabatrin  is  another 
anticonvulsant  that  increases  GABA  neurotransmission  but  this  time  by 
inhibiting  GABA  transaminase.  In  a  preliminary  open-label  trial  (n  =  20),  
vigabatrin  was  well  tolerated  and  was  associated  with  abstinence  from 
cocaine in 75% of those who remained in the study. Retention rate in this trial 
was low as only 40% of the enrolled participants completed the trial (Brodie et 
al.,2003).  It  is  a  drug  with  great  potentials  but  needs  to  be  tested  in 
adequately powered placebo controlled randomized studies.
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Tiagabine  is  yet  another  anticonvulsant  that  increases  GABA 
neurotransmission  by  blocking  the  presynaptic  reuptake  of  GABA.  In  2 
randomized  clinical  trials  involving  cocaine  dependent  patients  who  were 
maintained on  methadone, tiagabine (12-24mg/day) was found to decrease 
cocaine use compared with placebo (Gonzales et al., 2006; Gonzales et al., 
2003).
In  a clinical  trial  conducted in  cocaine dependents patients maintained on 
methadone  for  their  opioid  dependence,  buproprion  (300mg/day),  an 
antidepressant  potentiated  the  effects  of  contingency  management  in 
reducing cocaine, but did not have any effects in patients not assigned to 
contingency management (Poling et al., 2006). Finally, the use of stimulants 
has been tried for the treatment of cocaine dependence under the premise of 
a drug substitution for a drug with slower onset formulation and less abuse 
liability. Methylphenidate, a dopamine and nerepinephrine reuptake inhibitor 
used to treat attention deficit hyperactivity disorders (ADHD) was found to be 
no better than placebo in the treatment of cocaine dependent patients without 
comorbid  ADHD  (Grabowski  et  al.,  1997).  However  when  used  in  a 
population with  dual  diagnosis  of  cocaine dependence and ADHD, results 
from clinical trials were mixed. While a controlled clinical trial using immediate 
release methylphenidate (90mg/day) found no difference between the active 
drug  and  placebo  groups  (Schubiner  et  al.,  2002),  another  trial  using 
sustained  release  methylphenidate  (60mg/day),  found  significant 
improvement  in  ADHD  symptoms  that  were  associated  with  decrease  in 
cocaine use compared with placebo (Levin et al., 2007).
Though medications such as those that facilitate gabaergic function, modulate 
dopaminergic  function  or  act  as  an  agonist  replacement  therapy  show 
promise  in  treating  cocaine  dependence,  there  are  certain  drawbacks 
(Johnson BA, 2004). First, the majority of these drugs are still in their infancy 
stage with regard to testing their clinical utility for the treatment of cocaine 
dependence, second, all drugs tested are delivered orally, and those going 
through withdrawal may have trouble with ingestion due to vomiting (Johnson 
BA, 2004). Other adverse side effects associated with the use of medications 
may affect compliance in general. Some of the side effects associated with 
the  use  of  anticonvulsant  drugs  include  difficulty  with  attention  and 
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concentration (Johnson et al., 2007) which may increase craving to use more 
cocaine  to  offset  those  undesirable  side  effects  Furthermore,  individuals 
prone to abuse may attempt to get a pleasurable effect from taking more of 
the  treatment  drug  than  prescribed  [19].  Current  research  using  these 
pharmacotherapies  show  great  promise,  but  are  largely  based  on  small 
sample sizes, have limited research control, and still have a relatively low rate 
of  retention.  Also,  longitudinal  data  is  lacking  to  determine  the  enduring 
positive  effects  of  the  drugs  due  to  patient  displacement,  convenience  of  
appointments,  and  budgets.  While  CBT  has  shown  promise  and  some 
pharmacotherapies  have  shown  utility  in  treating  cocaine  dependence, 
neither  have  independently  established  solid   effectiveness  for  drug 
treatment.
4. Psychosocial/behavioral therapies
A  number  of  psychosocial  interventions  based  on  cognitive-behavioral 
approaches have received significant empirical attention in the literature on 
cocaine  use  disorders  in  the  last  two  decades  (Dutra  et  al.,  2008;  Crits-
Cristoph et al., 1999). These standardized interventions have been tailored to 
the unique challenges associated with cocaine use disorders.
 The  neurobiology  of  cocaine  addiction,  the  environment  in  which  the 
addiction occurs, and other resultant behavioral characteristics contribute to 
particular  difficulty  in  treating  the  cocaine  addicted  patient.  Thus,  the 
therapies developed to treat this disorder address these challenges directly 
and include strategies to help patients clarify their ambivalence about using 
motivational interviewing/motivational enhancement therapy; (MI/MET; Crits-
Cristoph et al., 1999, McKee et al., 2007), cope more effectively without using 
cocaine cognitive-behavioral therapy (CBT; Carroll et al., 1998; Grant et al.,  
1996;  Moeller  et  al.,  2005;  Messina  et  al.,  2003;  McKee  et  al.,  2007; 
Rohsenow et  al.,  2000;  Rawson  et  al.,  2002;  Carroll  et  al.,  2004),  think 
differently about their use behavior (cognitive therapy; CT; Crits-Cristoph et 
al.,19999;  Beck  et  al.,  1993)  utilize  techniques  to  avoid/prevent  triggers 
and/or the use behavior (CBT), change the reinforcing contingencies in their 
environment  (Contingency  Management/The  Community  Reinforcement 
Approach; CM/CRA; Carroll et al., 1998; Messina et al., 2003; Rawson et al.,  
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2002; Barry et al.,  2009) and increase awareness of and detachment from 
sensations, thoughts, and cravings that may lead to use, in order to prevent 
cocaine use (Meditation/Mindfulness Therapies; MMT; Rohsenow et al.,2000; 
Rohsenowet al., 2004). 
A  recent  meta-analysis  of  psychosocial interventions  for  substance  use 
disorders,  Dutra  and colleagues  (Dutra  et  al.,2008)  found  that  these 
psychosocial  interventions typically produce moderate to large effect sizes, 
demonstrating  their  efficacy  in  treating  cocaine  use disorders.  Below  we 
review and compare these psychosocial interventions, beginning with  CBT 
then MI/MET, CM/CRT and finally MMT.
4.1. Cognitive Behavioral Therapy (CBT)
Clinical evidence indicates the efficacy of CBT in those trying to overcome 
cocaine dependence (Crits-Cristoph et al.,  1999; Rawson et al.,  2002)  as 
well as cigarette smoking, methamphetamine use, and alcohol use disorders 
(Maude-Griffin et al., 1998). CBT has been found to be more effective than 
Interpersonal Therapy (IPT) in reducing frequency of cocaine use (Barry et  
al., 2009).
Rohsenow et al. (2004) found that brief (6 session) coping skills training was 
more effective than relaxation/meditation training in reducing cocaine use for 
up to 6 months, although these effects did not persist at 7-9 month follow-up 
or 12 month follow-up.
Crits-Cristoph and colleagues (1999)  found that  CT + group drug therapy 
(GDC) was no more effective than GDC alone and was equivalent to other 
treatments (Supportive- Expressive Therapy) in terms of promoting cocaine 
abstinence for 30 consecutive days during treatment, and 30, 60, and 90 day 
abstinence  post-treatment.  Rohsenow  et  al.  (2004)  failed  to  find  overall 
beneficial effects of coping skills training vs drug education, although women 
who received coping skills training were less likely to resume cocaine use and 
more likely to maintain abstinence than women who received drug education. 
Carroll  and colleagues (1998) found that CBT was no more effective than 
twelve-step facilitation (TSF) in terms of reducing cocaine use or promoting 
abstinence, although Maude-Griffin et al. (1998) found that individuals who 
received CBT were more likely to be abstinent for cocaine for 4 consecutive 
22
weeks and through six-month follow-up than those who received a twelve 
step facilitation (TSF) program. 
Cognitive behavioral  therapy (CBT) focuses on specific learning processes 
and teaching users new skills to cope with high-risk situations in an effort to 
achieve  abstinence.  This  treatment  method  is  goal-oriented,  flexible,  and 
individualized to meet the needs and schedule of the patient.
The interactive approach of CBT orients users to the program, asking them to 
create  goals  and  set  up  a  cognitive  baseline  for  themselves  in  terms  of 
confidence and commitment. This information is also useful to the therapist in 
matching therapeutic tasks to the specific needs of the patient. Looking at 
past,  present,  and future  cocaine use associated  habits,  and triggers,  the 
patient and the therapist formulate effective coping strategies and emergency 
plans to mediate the impact of cocaine-related stress situations in pursuit of 
abstinence.  Utilizing  principles  of  classical  and  operant  conditioning,  the 
therapist works with the patient to customize a strategy to meet the goal of 
treatment: to unlearn old, ineffective behaviors, and learn new ones (Carroll et 
al., 1998).
Over the weeks of structured therapy, specific techniques are used in CBT to 
achieve and maintain abstinence and program retention (Carroll et al., 1998). 
These techniques include developing problem-solving skills, decision-making 
skills,  improving  social  skills,  and  implementing  thought  management  and 
coping skills to support refusing use and managing cravings (Carroll et al., 
1998). In CBT, a lapse is not considered a failure, but rather an indication that 
the patient or user must further practice and rehearse the skills learned in 
treatment to prevent the lapse from turning into a relapse (Penberthy and 
Wartella, 2007).
CBT is intended for those committed to reducing or eliminating their use of 
harmful substances. Empirical support for CBT shows that its effects appear 
to endure up to a year following treatment and patients demonstrate higher 
post-treatment coping skills, compared to subjects receiving other types of 
therapy (Rawson et al., 2002; Carroll et al., 2005; Epstein et al.,2003). 
Patient  commitment  is  integral  to  the  success  of  CBT.  In  fact,  Carroll 
demonstrated that participants who complete more homework assignments 
show significantly greater increases in the effectiveness and quantity of their 
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coping  skills  with  respect  to  substance  use,  have  greater  treatment 
adherence  and  use  less  cocaine  during  treatment  and  through  a  1-year  
follow-up (Carroll et al., 2005). This demonstrated commitment of subjects in 
an important factor to CBT’s efficacy. Indeed,completing homework has been 
shown to be associated with more positive immediate and enduring outcomes 
(Carroll et al., 2005), and failure to participate and practice may result in less 
retention of skills and relapse (Carroll et al., 1998; Carroll et al., 2005).
4.2  Contingency  Management  (CM)  &  the  Community  Reinforcement 
Approach (CRA)
A  behavioral  intervention  utilizing  the  principles  of  operant  conditioning, 
Contingency Management (CM) and the Community Reinforcement Approach 
(CRA) involves rewarding individuals for periods of abstinence (i.e. providing 
cocaine-free urine samples) with vouchers or variable reinforcement methods 
(i.e.  drawings  from  a  prize  bowl,  lottery  tickets:  Meyers  and  Squires 
1995/2001), often with increasing rewards for longer periods of abstinence 
(Barry et al., 2009; DeRubeis and Crits-Cristoph, 1998; Petry et al., 2005). As 
part of CRA, CM techniques are combined with counseling that integrates the 
behavioral aspects of CBT, offering individuals direct, tangible incentives for 
their  behavior  designed  to  promote  abstinence  during  treatment  and 
experience  abstinence  as  rewarding  (Meyers  and  Squires,  1995/2001). 
Research on CRA for cocaine abuse and dependence has demonstrated the 
efficacy of this method across different populations of individuals with cocaine 
dependence (Barry et al., 2009; DeRubeis and Crits-Cristoph, 1998; Roozen 
et al., 2004).
Prendergast  and  colleagues  (2006)  in  their  meta-analysis  on  CRA  for 
substance  use  disorders,  the  authors  found  that  use  of  vouchers  in 
participants  with  cocaine  dependence  was  associated  with  medium effect 
sizes.  CRA  plus  vouchers  has  been  found  to  more  effective  than  other 
standard treatments including methadone maintenance (Rawson et al., 2002; 
Barry et  al.,  2009)  and TSF/standard  drug counseling (Petry  et  al.,  2005; 
Higgins  et  al.,  1993,  1995,  2000;  Secades-Villa  et  al.,  2008),  even  after 
accounting  for  differential  rates  of  attrition  between  groups.  These  results 
have persisted over multiple follow-up points (Barry et al., 2009; petry et al.,  
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2005).  In  a series of studies conducted by Higgins and colleagues (1995, 
2000,  2003,  2006),  this  set  of  authors  found  that  CRA  plus  vouchers 
consistently produces higher rates of retention over other treatments (Higgins 
et al., 1993; Higgins et al., 2006).
Research examining the role of vouchers in CRA conducted by Higgins and 
colleagues (1995, 1994) found that CRA alone was less effective than CRA 
plus  vouchers  with  respect  to  promoting  treatment  completion  and 
abstinence. However, these differences were not maintained at follow-up in 
either study, casting doubt on the long-term efficacy of CRA with vouchers in 
comparison to behavioral-based counseling. In another study conducted by 
Higgins (Higgins et al., 2000), CRA with contingent vouchers was found to be 
superior to three control conditions (one of which was CRA alone) in terms of  
abstinence in-treatment and 6 month follow-up. However, the authors did not 
report if there were differences between specific control conditions and the 
CRA plus vouchers condition, leaving questions about the long-term impact of 
CRA plus  vouchers  over  CRA alone.  In  a  series  of  studies  exploring  the 
impact of contingent (abstinence-based) and non-contingent vouchers as part 
of CRA on treatment outcomes, Higgins and colleagues (2000), found that 
CRA  plus  vouchers  was  more  effective  than  CRA  with  non-contingent 
vouchers in terms of in-study abstinence and abstinence during the course of 
6  and  18  month  follow-up,  although  one  of  these  investigations  included 
multiple conditions combined into the control group (Higgins et al., 2000). In a 
comparable study by Jones e coll. (2004), individuals who received both CBT 
and  vouchers  (CM)  were  more  likely  to  abstain  from cocaine  and  obtain 
longer  periods  of  abstinence  than  those  who  received  CBT  and  non-
contingent vouchers, although follow-up data was not available.
In a recent investigation of the effects of different levels of vouchers as part of  
CRA, two sets of authors (Higgins et al., 2006; Garcia-Rodriguez et al., 2009) 
investigated  the  role  of  low  vs  high  vouchers.  Both  studies  found  that 
participants who received higher levels of vouchers were more likely to be 
abstinent  during  the  study,  with  medium-to-large  effect  size  (Garcia-
Rodriguez et al., 2009) . Differences between the voucher groups were not 
significantly  different  during  treatment  in  both  studies  and  Higgins  et  al.  
(2006) found that differences between the groups were not significant at the 
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conclusion of treatment,  although the high voucher group did demonstrate 
somewhat higher rates of abstinence across thev 18 month follow-up period.  
However, Garcia-Rodriguez and colleagues (2009) did not provide follow-up 
data,  leaving  questions  about  the  long-term impact  of  CRA regardless  of  
voucher level on long-term abstinence.
4.3. Combination of CBT and CM/CRA 
Higgins and colleagues (1994)  compared the efficacy of  a  combination of 
coping  skills  training,  CRA  and  community  reinforcement  (CR;  rewarding 
abstinence  with  prosocial  activities  with  friends/family)  with  standard 
individual/group  drug  counseling.  They  found  that  this  combination  of 
behavioral interventions was superior to treatment as usual drug counseling 
in promoting and maintaining abstinence over the 24 weeks of the program. 
In  this  study,  58% of  the  CRA +  vouchers  participants  completed the  24 
weeks of therapy as compared to 11% of the drug counseling group (Higgins 
et al., 1994), with nearly half of the CRA + vouchers participants achieving 16 
weeks of abstinence, but only 5% of the drug counseling group achieving this 
goal. However, the researchers did not provide follow-up data post-treatment 
and the differential rates of attrition between groups may account for some of 
the differences between the groups.
Similar  results  were  found  by  Carroll  et  al.  (1994)  in  a  recent  study  of 
computer-assisted CBT on substance dependence  vs  individual/group drug 
counseling in individuals with cocaine and other substance dependence.
They found that those who received CBT demonstrated lower levels of drug 
use during the study and at follow-up, with a significant interaction between 
group and time, even when controlling for treatment exposure.  There was 
also a direct relationship between number of CBT modules completed and 
maximum days of abstinence from drugs. These results indicate that CBT 
may have a “sleeper effect”  of  CBT over  time on substance dependence, 
promoting reductions in use even after the completion of treatment (Rawson 
et al., 2002; Epstein et al., 2003; Higgins et al., 1994; Carroll et al., 1994). 
These results suggest that while skills learned in CBT may take time to be 
incorporated into one’s behavior,  the use of  incentives in conjunction with 
CBT may be beneficial in establishing short-term gains (DeRubeis and Crits-
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Cristoph, 1998). Higgins found that of patients receiving vouchers for cocaine-
free  urine  at  their  scheduled  CBT  session,  75%  competed  24  weeks  of 
treatment as compared to 40% in the CBT-only group.
Furthermore,  the  CBT+CRA  group  recorded  significantly  greater 
improvements of the ASI scale and longer periods of abstinence during the 
study (DeRubeis and Crits-Cristoph, 1998). 
With respect to cocaine dependence, CBT demonstrates great utility (Crits-
Cristoph et al., 1999; Rawson et al., 2002), and its efficacy and durability has 
been tested and empirically supported (Carroll et al., 1998). Despite strong 
evidence for the efficacy of CBT, this modality is not without its limitations. 
The positive benefits of CBT take time to assimilate, requiring much practice 
and  patience,  often  requiring  weeks  or  months  to  show  maximum 
effectiveness. CBT is not for everyone. Subjects with low abstract reasoning 
skills  may  not  receive  the  full  benefits  of  treatment  (Maude-Griffin  et  al., 
1998). This is problematic for individuals who use cocaine, as according to a 
matched-pairs  study  by  O’Malley  using  standardized  neuropsychological 
assessment procedures, 50% of cocaine abusers, scored in the ‘impaired’ 
range  on  the  summary  index  of  the  Neuropsychological  Screening  Exam 
(Aharanovich et al., 2003).
Messina et al. (2003)  found that CBT+CRA was no more effective than CRA 
or  CBT alone in  producing  cocaine-free  urine  samples  during  their  study,  
although it was superior to MM. However, over the course of 6 month and 12 
month  follow-up  that  those  in  the  CBT+CRA  group  who  did  not  have 
antisocial personality disorder (ASPD) experienced declines in abstinence on 
par  with  those  who  received  CRA  only,  with  CBT  demonstrating  greater 
efficacy than CBT+CRA over time. Individuals with ASPD demonstrated fewer 
differences at follow-up, with CBT+CRA showing increases in abstinence over 
time that surpassed CRA only at 1 year follow-up and were comparable to 
CBT  only.  Rawson  (2002)  found  that  the  combination  of  CRA+CBT 
demonstrated greater effectiveness than MM in producing cocaine-free and 
short-term abstinence and was superior to CBT alone during the study. Those 
who  received CRA+CBT also  attended more  sessions than those in  CBT 
only.  A 6 month follow-up, the CRA+CBT group was equivalent to CBT on 
outcome measures, although at 12 months, individuals in the combined group 
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were  less  successful  than CBT only (and equivalent  to  CRA)  in  reducing 
cocaine use. There was no evidence that CRA+CBT was superior over the 
long-term to either CRA or CBT alone. Again, this demonstrates the enduring 
power  of  CBT and  the  fact  that  it  may  take  some time  to  be  effectively 
incorporated  into  the  recovering  individuals’  daily  behavioral  and  thought 
patterns.
4.4. CBT versus CM 
Rawson  and  colleagues  (2002)  investigated  the  comparative  efficacy  of 
Contingency  (CM)  and  CBT  (alone  and  in  combination)  vs  methadone 
maintenance (MM).
Individuals who received CM (alone or with CBT) were more likely to maintain 
their abstinence in treatment compared to the MM only group and CM only 
was superior to MM in promoting abstinence at the end of treatment However,  
the  superiority  of  CM dissipated  over  the  12  month  follow-up  period.  No 
significant differences between any of the groups were evident at 6 month 
follow-up and CM and CM+CBT were found to be no more effective than MM 
at 12 month follow-up.
In  a  similar  study  conducted  by  Messina  (2003)  on  the  comparative 
effectiveness of CBT, and CM (alone and in combination) to MM in those with 
and without ASPD, the authors found no main effect of treatment condition on 
rates of abstinence overall, although individuals with ASPD who received CM 
only,  CBT only  or  CM+CBT were  more  likely  to  be  abstinent  than  those 
receiving MM only, and that CM only superior to CBT and MM and equivalent 
to CBT+CM with respect to in-treatment abstinence. Over the course of 12 
month follow-up, individuals with ASPD in the CBT only and CM+CBT groups 
demonstrated increases in abstinence, while those in the CM only condition 
demonstrate  slightv  decreases in  abstinence over  time.  Although all  three 
treatment conditions were  superior  to  MM only,  there were  no statistically 
significant differences between groups at the 12 mo. follow-up point. Among 
those  without  ASPD,  those  in  the  CM  only  and  CBT+CM  groups 
demonstrated increases in abstinence in the 6 months following treatment vs 
other  groups.  However,  at  12  month  follow-up,  CBT  only  produced  the 
highest  rates  of  abstinence  and  those  who  received  CM-based  therapies 
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were  the least  likely  to  remain  abstinent  of  all  four  groups.  These results 
suggest  that  individuals  with  ASPD may respond more  effectively  to  CM-
based therapies over both the short  and long-term, although in individuals 
without ASPD, CBT alone may produce superior outcomes over time.
Overall,  CRA-based interventions have demonstrated efficacy in promoting 
greater treatment retention and abstinence during treatment.  However,  the 
mechanisms  by  which  CRA  works  (including  the  role  of  behavioural 
components  of  CRA)  have  received  relatively  little  attention,  creating 
challenges in isolating the effective components of CRA. Differential retention 
rates  across  groups  based  on  use  of  vouchers  may  account  for  some 
differences  in  rates  of  abstinence  between  groups,  making  it  difficult  to 
identify whether treatment retention may serve as a confounding variable in 
outcomes. Methodological differences between studies regarding changes in 
the reinforcement schedule regarding the value and type of vouchers (Higgins 
et al., 1995, 2000, 2003, 2006), as well as the use of supplemental vouchers  
for providing urine samples regardless of condition or abstinence (Higgins et 
al., 2006) may serve as additional confounds in these studies regarding the 
influence of CM on cocaine use. The costs of the incentives  used in CM and 
CRA can be substantial  even for short-term treatment,  often with  costs of 
$1,000 or more per individual (Messina et al.,  2003; Rawson et al.,  2002; 
Higgins et al., 2000), although recent research has demonstrated that lower 
vouchers  levels  may still  be  effective  in  promoting  intreatment  abstinence 
(Barry et al., 2009; Higgins et al., 2006). Given the lack of data on the long-
term efficacy of CM/CRA in comparison to other psychosocial treatments, CM 
only approaches may be of limited efficacy in producing long-term abstinence, 
as  individuals  with  cocaine dependence may find  themselvescontinuing  to 
lack  the  skills  and  knowledge  needed  to  long-term  changes  in  behavior 
unless they also receive therapy that teaches coping skills through cognitive 
and/or behavioral strategies associated with CBT or CRA.
4.5. Motivational Enhancement/Motivational Interviewing
Motivational  interventions,  including  motivational  enhancement  (ME)  and 
motivational interviewing (MI) focus on enhancing motivation to change long-
standing drug use behaviors (Miller and Rollnick, 1991) and has been widely 
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applied to substance use disorders, demonstrating medium-sized effects in 
reducing use (Miller and Rollnick, 1991). ME/MI employs a directive, client-
centered  approach  that  focuses  on  expressing  empathy,  developing 
discrepancy between current behavior and goals, rolling with resistance and 
supporting self-efficacy (Miller and Rollnick, 1991) in an effort to explore and 
resolve  resistance  to  making  changes  in  use  and  use-related  behaviors. 
Stotts and colleagues (2001) found that a 2 session MI intervention promoted 
the development of healthy coping skills and reduced cocaine use, with those 
low in initial motivation to change were most likely to benefit from MI with 
respect to completing treatment.
However,  Rohsenow  et  al.  (2000)  failed  to  find  any  overall  differences 
between MET and CST (coping skills training) on cocaine-related outcomes, 
although  MET  was  more  efficacious  for  individuals  low  in  motivation  to 
change than those high in motivation to change.
4.6. CBT vs MET/MI
McKee  and  colleagues  (2007)  studied  the  additive  effects  of  motivational 
enhancement therapy (MET) to CBT in a study of individuals with cocaine 
abuse  or  dependence.  They  found  no  differences  in  retention  between 
groups, although those in the CBT+MET condition were more likely to seek 
out  further  drug  treatment  after  completion  of  the  study.  Those  receiving 
CBT+MET also reported a greater desire for abstinence and expectations for 
success, despite anticipating more challenges to their long-term abstinence. 
However, these differences were not maintained during follow-up. In terms of 
cocaine use, both CBT and CBT+MET had equivalent outcomes in terms of 
frequency and quantity of use and number of cocaine-positive urines during 
treatment or at follow-up. Despite strong results and corroboration by other 
studies, this study was limited by a small sample size.
The relatively small body of research on motivational-based interventions for 
cocaine dependence preludes a definitive analysis of the effectiveness of MI 
or  MET  as  stand-alone  interventions  for  cocaine  dependence,  with  very 
limited evidence that MET may serve to promote engagement in therapy and 
more  positive  attitudes  about  the  change  process  when  combined  with 
interventions such as CBT.
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4.7. Meditation/Mindfulness-Based Therapies
So-called  “third  wave”  behavioral  therapies,  including  Acceptance  and 
Commitment  Therapy  (ACT),  Dialectical  Behavior  Therapy  (DBT), 
Mindfulness-Based Stress Reduction (MBSR) and Transcendental Meditation 
(TM) thus far received less empirical attention as treatments for reducing use 
in individuals with cocaine dependence.
Hypothesized  to  increase awareness  of  and  detachment  from sensations, 
thoughts,  and  cravings  that  may  lead  to  use,  psychosocial  interventions 
incorporating  mindfulness  and/or  meditation  have  been  associated  with 
reductions in  substance use primarily  among non-abusing,  non-dependent 
populations (Aron and Aron,  1980;  Genderloos et  al.,  1991;  Hawkins  MA, 
2003).  However,  well-controlled  studies  investigating  the  impact  of 
meditation/mindfulness-based  interventions  for  substance  use  disorders  or 
comparing the relative efficacy of these interventions to other treatments are 
rare.  Although  a  small  number  of  studies  do  exist  (Dimeff  et  al.,  2000; 
Linehan  et  al.,  2002;  Taub  et  al.,  1994),  only  two  published  studies 
(Rohsenow et  al.,  2000,  2004)  focus specifically  on  cocaine dependence. 
Unfortunately,  both  of  these  studies  used  “meditation-relaxation”  condition 
that did not explicitly include meditation training or aspects of ACT or DBT. As 
such, there currently exists a dearth of literature about the effectiveness of 
meditation  and  mindfulness-based  therapies  for  treatment  of  cocaine 
dependence.
When  all  studies  are  evaluated  there  are  definitely  trends  towards 
effectiveness, but there are strengths and weaknesses to consider for each 
study as well.
5.  Treating  cocaine  addiction  with  a  cognitive-behavioral  approach  : 
Katleen Carroll’s technique.
Cognitive-behavioral  coping skills treatment (CBT) is a short-term, focused 
approach to helping cocaine-dependent individuals (In this manual, the term 
cocaine abuser or cocaine-dependent individual is used to refer to individuals 
31
who  meet  DSM-IV  criteria  for  cocaine  abuse  or  dependence.)  become 
abstinent from cocaine and other substances.
 The underlying assumption is that learning processes play an important role 
in  the  development  and  continuation  of  cocaine  abuse  and  dependence. 
These same learning processes can be used to help individuals reduce their 
drug use. Very simply put, CBT attempts to help patients recognize, avoid, 
and cope.
That  is,  RECOGNIZE the  situations  in  which  they  are  most  likely  to  use 
cocaine,  AVOID these  situations  when  appropriate,  and  COPE more 
effectively with  a range of problems and problematic behaviors associated 
with substance abuse.
Several  important  features  of  CBT  make  it  particularly  promising  as  a 
treatment for cocaine abuse and dependence:
• CBT is a short-term, comparatively brief approach well  suited to the 
resource capabilities of most clinical programs.
• CBT has been extensively evaluated in rigorous clinical trials and has 
solid empirical support as treatment for cocaine abuse. In particular, 
evidence  points  to  the  durability  of  CBT’s  effects  as  well  as  its 
effectiveness  with  subgroups  of  more  severely  dependent  cocaine 
abusers.
• CBT  is  structured,  goal-oriented,  and  focused  on  the  immediate 
problems  faced  by  cocaine  abusers  entering  treatment  who  are 
struggling to control their cocaine use.
• CBT is a flexible,  individualized approach that  can be adapted to a 
wide  range  of  patients  as  well  as  a  variety  of  settings  (inpatient, 
outpatient) and formats (group, individual).
• CBT is compatible with a range of other treatments the patient may 
receive, such as pharmacotherapy.
• CBT’s broad approach encompasses several important common tasks 
of successful substance abuse treatment.
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5.1. Components of CBT
CBT has two critical components: functional analysis and skill training.
Functional analysis
For each instance of cocaine use during treatment, the therapist and patient 
do a functional analysis, that is, they identify the patient’s thoughts, feelings, 
and circumstances before and after the cocaine use. Early in treatment, the 
functional  analysis  plays  a critical  role in helping the patient and therapist 
assess  the  determinants,  or  high-risk  situations,  that  are  likely  to  lead  to 
cocaine use and provides insights into some of the reasons the individual 
may  be  using  cocaine  (e.g.,  to  cope  with  interpersonal  difficulties,  to 
experience risk or euphoria not otherwise available in the patient’s life). Later 
in  treatment,  functional  analyses  of  episodes of  cocaine  use may identify 
those situations or states in which the individual still has difficulty coping.
Skills training
CBT can be thought of as a highly individualized training program that helps 
cocaine abusers unlearn old habits associated with cocaine abuse and learn 
or relearn healthier skills and habits. By the time the level of substance use is 
severe enough to warrant treatment, patients are likely to be using cocaine as 
their  single  means  of  coping  with  a  wide  range  of  interpersonal  and 
intrapersonal problems. This may occur for several reasons:
• The individual may have never learned effective strategies to cope with the 
challenges and problems of adult life, as when substance use begins during 
early adolescence.
• Although the individual may have acquired effective strategies at one time, 
these skills may have decayed through repeated reliance on substance use 
as  a  primary  means  of  coping.  These  patients  have  essentially  forgotten 
effective strategies because of chronic involvement in a drug-using lifestyle in 
which the bulk of their time is spent in acquiring, using, and then recovering 
from the effects of drugs.
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•  The individual’s ability to use effective coping strategies may beweakened 
by  other  problems,  such  as  cocaine  abuse  with  concurrent  psychiatric 
disorders.
Because cocaine abusers are a heterogeneous group and typically come to 
treatment with a wide range of problems, skills training in CBT is made as 
broad  as  possible.  The first  few sessions  focus  on  skills  related  to  initial  
control of cocaine use (e.g., identification of high-risk situations, coping with 
thoughts about cocaine use). Once these basic skills are mastered, training is 
broadened to include a range of other problems with which the individual may 
have difficulty coping (e.g.,  social  isolation, unemployment).  In addition, to 
strengthen and broaden the individual’s range of coping styles, skills training 
focuses on both intrapersonal (e.g.,  coping with craving) and interpersonal 
(e.g., refusing offers of cocaine) skills. Patients are taught these skills as both 
specific strategies (applicable in the here and now to control cocaine use) and 
general strategies that can be applied to a variety of other problems. Thus, 
CBT  is  not  only  geared  to  helping  each  patient  reduce  and  eliminate 
substance use while in treatment, but also to imparting skills that can benefit 
the patient long after treatment.
5.2. Critical Task
CBT  addresses  several  critical  tasks  that  are  essential  to  successful 
substance abuse treatment (Rounsaville and Carroll 1992).
•  Foster  the  motivation  for  abstinence.  An  important  technique  used  to 
enhance the patient’s motivation to stop cocaine use is to do a decisional 
analysis which clarifies what the individual stands to lose or gain by continued 
cocaine use.
• Teach coping skills. This is the core of CBT - to help patients recognize the 
high-risk situations in which they are most likely to use substances and to 
develop other, more effective means of coping with them.
• Change reinforcement contingencies. By the time treatment is sought, many 
patients  spend  most  of  their  time  acquiring,  using,  and  recovering  from 
cocaine use to the exclusion of other experiences and rewards. In CBT, the 
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focus  is  on  identifying  and  reducing  habits  associated  with  a  drug-using 
lifestyle by substituting more enduring, positive activities and rewards.
•  Foster  management  of  painful  affects.  Skills  training  also  focuses  on 
techniques  to  recognize  and  cope  with  urges  to  use  cocaine;  this  is  an 
excellent model for helping patients learn to tolerate other strong affects such 
as depression and anger.
•  Improve  interpersonal  functioning  and  enhance  social  supports.  CBT 
includes training in a number of important interper sonal skills and strategies 
to help patients expand their  social  support  net works and build enduring, 
drug-free relationship.
5.3. Parameters of CBT
Format
An individual format is preferred for CBT because it allows for better tailoring 
of treatment to meet the needs of specific patients.  Patients receive more 
attention and are generally more involved in treatment when they have the 
opportunity to work with and build a relationship with a single therapist over 
time. Individual treatment affords greater flexibility in scheduling sessions and 
eliminates  the  problem  of  either  having  to  deliver  treatment  in  a  “rolling 
admissions” format or asking patients to wait  several weeks until  sufficient 
numbers of patients are recruited to form a group. Also, the comparatively 
high rates of retention in programs and studies may reflect, in part, particular 
advantages of individual treatment.
However,  a  number  of  researchers  and  clinicians  have  emphasized  the 
unique benefits of delivering treatment to substance users in the group format 
(e.g., universality, peer pressure). It is relatively straightforward to adapt the 
treatment  described  in  this  manual  for  groups.  This  generally  requires 
lengthening the sessions to 90 minutes to allow all group members to have an 
opportunity to comment on their personal experiences in trying out skills, give 
examples,  and  participate  in  role-playing.  Treatment  will  also  be  more 
structured in a group format because of the need to present the key ideas and 
skills in a more didactic, less individualized format.
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Length
CBT has been offered in  12 to  16 sessions,  usually over  12 weeks.  This 
comparatively  brief,  short-term  treatment  is  intended  to  produce  initial 
abstinence and stabilization. In many cases, this is sufficient to bring about 
sustained improvement for as long as a year after treatment ends. Preliminary 
data  suggest  that  patients  who  are  able  to  attain  3  or  more  weeks  of 
continuous abstinence from cocaine during the 12-week treatment period are 
generally able to maintain good outcome during the 12 months after treatment 
ends.
For  many  patients,  however,  brief  treatment  is  not  sufficient  to  produce 
stabilization  or  lasting  improvement.  In  these  cases,  CBT  is  seen  as 
preparation  for  longer  term  treatment.  Further  treatment  is  recommended 
directly when the patient requests it or when the patient has not been able to 
achieve  3  or  more  weeks  of  continuous  abstinence  during  the  initial 
treatment.
Additional booster sessions of CBT during the 6 months following the initial 
treatment  phase  improves  outcome.  The  maintenance  version  of  CBT 
focuses on the following:
•  Identifying  situations,  affects,  and cognitions  that  remain  problematic  for 
patients  in  their  efforts  to  maintain  abstinence  or  which  emerge  after 
cessation or reduction of cocaine use.
•  Maintaining gains through solidifying the more effective coping skills and 
strategies the subject has implemented.
•  Encouraging  patient  involvement  in  activities  and  relationships  that  are 
incompatible with drug use. Rather than introducing new material or skills, the 
maintenance version of CBT focuses on broadening and mastering the skills 
to which the patient was exposed during the initial phase of treatment.
Setting
Treatment is usually delivered on an outpatient basis for several reasons:
• CBT focuses on understanding the determinants of substance use, and this 
is best done in the context of the patient’s day-to-day life. By understanding 
who  the  patients  are,  where  they  live,  and  how  they  spend  their  time, 
therapists can develop more elaborate functional analyses.
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• Skills training is most effective when patients have an opportunity to practice 
new skills and approaches within the context of their daily routine, learn what  
does  and  does  not  work  for  them,  and  discuss  new  strategies  with  the 
therapist.
Patients
CBT  has  been  evaluated  with  a  broad  range  of  cocaine  abusers.  The 
following are generally  not appropriate  for CBT delivered on an out-patient 
basis:
-Those who have psychotic  or  bipolar disorders and are not  stabilized on 
medication
-Those who have no stable living arrangements
-Those who are not medically stable (as assessed by a pretreatment physical  
examination)
-Those who have other concurrent substance dependence disorders, with the 
exception of alcohol or marijuana dependence
No  significant  differences  have  been  found  in  outcome  or  retention  for 
patients  who  seek  treatment  because  of  court  or  probation  pressure  and 
those who have DSM-IV diagnoses of antisocial personality disorder or other 
Axis II disorders, nor has outcome varied by patient race/ethnicity or gender.
Compatibility With Adjunctive Treatments
CBT  is  highly  compatible  with  a  variety  of  other  treatments  designed  to 
address a range of comorbid problems and severities of cocaine abuse:
• Pharmacotherapy for cocaine use and/or concurrent psychiatric disorders
•  Self-help  groups  such  as  Cocaine  Anonymous  (CA)  and  Alcoholics 
Anonymous (AA)
• Family and couples therapy
• Vocational counseling, parenting skills, and so on
When CBT is provided as part of a larger treatment package, it is essential for 
the CBT therapist to maintain close and regular contact with other treatment 
providers.
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5.4. Basic principles of CBT
CBT is collaborative. The patient and therapist consider and decide together 
on  the  appropriate  treatment  goals,  the  type  and  timing  of  skills  training, 
whether a significant other is brought into some of the sessions, the nature of 
outside practice tasks, and so on. Not only does this foster the development 
of  a good working relationship and avoid an overly passive stance by the 
therapist, but it also assures that treatment will be most useful and relevant to 
the patient.
CBT is based on social learning theory. It is assumed that an important factor 
in how individuals begin to use and abuse substances is that they learn to do 
so. The several ways individuals may learn to use drugs include modeling, 
operant conditioning, and classical conditioning.
Modeling. People  learn  new  skills  by  watching  others  and  then  trying  it 
themselves. For example, children learn language by listening to and copying 
their parents. The same may be true for many substance abusers. By seeing 
their  parents use alcohol,  individuals may learn to  cope with  problems by 
drinking.  Teenagers  often  begin  smoking  after  watching  their  friends  use 
cigarettes. So, too, may some cocaine abusers begin to use after watching 
their friends or family members use cocaine or other drugs.
Operant Conditioning Laboratory  animals  will  work  to  obtain  the  same 
substances that many humans abuse (cocaine, opiates, and alcohol) because 
they find exposure to the substance pleasurable, that is, reinforcing. Drug use 
can  also  be  seen  as  behaviour  that  is  reinforced  by  its  consequences. 
Cocaine  may be  used  because  it  changes  the  way  a  person  feels  (e.g.,  
powerful,  energetic, euphoric, stimulated, less depressed), thinks (I can do 
anything, I can only get through this if I am high), or behaves (less inhibited,  
more confident).
The  perceived  positive  (and negative)  consequences  of  cocaine  use  vary 
widely from individual to individual. People with family histories of substance 
abuse,  a  high  need  for  sensation  seeking,  or  those  with  a  concurrent 
psychiatric disorder may find cocaine particularly reinforcing. It is important 
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that clinicians understand that any given individual uses cocaine for important  
and particular reasons.
Classical Conditioning  Pavlov  demonstrated  that,  over  time,  repeated 
pairings  of  one  stimulus  (e.g.,  a  bell  ringing)  with  another  (e.g.,  the 
presentation of food) could elicit a reliable response (e.g., a dog salivating). 
Over  time,  cocaine  abuse  may  become  paired  with  money  or  cocaine 
paraphernalia, particular places (bars, places to buy drugs), particular people 
(drug-using  associates,  dealers),  times  of  day  or  week  (after  work, 
weekends), feeling states (lonely, bored), and so on. Eventually, exposure to 
those cues alone is sufficient to elicit very intense cravings or urges that are 
often followed by cocaine abuse.
5.5. Relevant Domains
In  identifying  patients’  determinants  of  drug  abuse,  it  may  be  helpful  for 
clinicians to focus their inquiries to cover at least five general domains:
•  Social: With whom do they spend most of their time? With whom do they 
use  drugs?  Do  they have  relationships  with  those  individuals  that  do  not 
involve substance abuse? Do they live with  someone who is a substance 
abuser? How has their social network changed since drug abuse began or 
escalated?
•  Environmental:  What are the particular environmental cues for their drug 
abuse  (e.g.,  money,  alcohol  use,  particular  times  of  the  day,  certain 
neighborhoods)?  What  is  the  level  of  their  day-to-day  exposure  to  these 
cues? Can some of these cues be easily avoided?
•  Emotional:  Research  has  shown  that  feeling  states  commonly  precede 
substance  abuse  or  craving.  These  include  both  negative  (depression, 
anxiety, boredom, anger) and positive (excitement, joy) affect states. Because 
many patients initially have difficulty linking particular emotional states to their 
substance abuse (or do so, but only at a surface level), affective antecedents 
of substance abuse typically are more difficult to identify in the initial stages of 
treatment.
• Cognitive: Particular sets of thought or cognition frequently precede cocaine 
use (I need to escape, I can’t deal with this unless I’m high, With what I am 
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going through I deserve to get high). These thoughts are often charged and 
have a sense of urgency.
•  Physical  :  Desire  for  relief  from  uncomfortable  physical  states  such  as 
withdrawal  has  been  implicated  as  a  frequent  antecedent  of  drug  abuse. 
While controversy surrounding the nature of physical withdrawal symptoms 
from cocaine dependence continues, anecdotally, cocaine abusers frequently 
report particular physical sensations as precursors to substance abuse (e.g., 
tingling  in  their  stomachs,  fatigue  or  difficulty  concentrating,  thinking  they 
smell cocaine).
5.6. The Structure and Format of Sessions
CBT is highly structured and is more didactic than many other treatments. 
Thus,  CBT  therapists  assume  a  more  directive  and  active  stance  than 
therapists conducting some other forms of substance abuse treatment.
A great deal of work is done during each session, including reviewing practice 
exercises, debriefing problems that may have occurred since the last session, 
skills training, feedback on skills training, in-session practice, and planning for  
the next week. This active stance must be balanced with adequate time for 
understanding and engaging with the patient.
20/20/20 Rule
To achieve a good integration of manual-driven and patient-driven material in 
each session, it has developed the “20/20/20 Rule” for the flow of a typical 60-
minute CBT session (30/30/30 Rule for the flow of a 90-minute group CBT 
session ) .
 During the first 20 minutes, therapists focus on getting a clear understanding 
of patients’ current concerns, level of general functioning, and substance use 
and  craving  during  the  past  week,  as  well  as  their  experiences  with  the 
practice  exercise.  This  part  of  the  session  tends  to  be  characterized  by 
patients doing most of the talking, although therapists guide with questions 
and reflection as they get a sense of the patients’ current status.
40
The  second  20  minutes  is  devoted  to  introduction  and  discussion  of  a 
particular skill. Therapists typically talk more than patients during this part of 
the  session,  although  it  is  critical  that  therapists  personalize  the  didactic 
material  and  check  back  with  patients  frequently  for  examples  and 
understanding.
The final 20 minutes reverts to being more patient dominated, as patients and 
therapists agree on a practice exercise for the next week and anticipate and 
plan for any difficulties the patients might encounter before the next session.
Topics
Eight  skill  topics  are  covered  in  CBT  for  cocaine  dependence  plus  a 
termination session and elective sessions that involve significant others. The 
sequence in which the topics are presented should be based on the clinical 
judgment of therapists and the needs of the patients. They are given here in 
the  sequence  most  often  used  with  cocaine  abusers.  The  most  critical 
behavioural  skills  for  patients  just  entering  treatment  are  introduced  first, 
followed by more general skills.
Since CBT is usually delivered in 12-16 sessions over 12 weeks, there are 
fewer  skills-training topics than sessions.  This  provides some flexibility  for 
therapists to allow for greater practice and mastery of a small but critical set 
of skills as well as repetition of session material as needed. It is intended to 
prevent patients from being overwhelmed with material.
Several skill guidelines are given for each session, many more than can be 
reasonably introduced. When delivered as a single session, therapists should 
carefully select skills to match the patients and not attempt to cover them all.
A therapist might pick one or two coping skills the patient has used in the past 
and introduce one or two more that are consistent with the patient’s coping 
style.
When delivered  in  more  than  one  session,  therapists  should  split  up  the 
guidelines, discussing and practicing the most basic and familiar skills in the 
first session and more challenging ones in the second. Moreover, the two-
session format allows patients to be introduced to a skill in the first session, 
practice  it  in  the  interval  before  the  next  session,  and  discuss  and  work 
through any difficulties during the second session. Practice exercises should 
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be given for both sessions, with the exercise for the second session being a 
variant of the first (e.g., trying out a skill not used the week before, increasing 
the difficulty or complexity of the task).
The eight skill topics are: 
1) Coping with craving; 2) Shoring up patients motivation and commitment to 
stop;  3) Refusal skills/ Assertiveness; 4) Seemingly Irrelevant Decisions; 5) 
An all-purpose coping plan; 6) Problemsolving; 7) Case Management; 8) HIV 
Risk reduction.
6. Adaptation of individual CBT  to the group treatment format 
6.1. Aim of the study
CBT is a short-term intervention, structured and focused on immediate 
and contingent problems faced by patients. 
In addition, to enhancing drug therapies (Karila et al., 2011; Sofuoglu, 2010), 
CBT proved to be flexible and able to adapt to individual patients, and also 
well  suited to be integrated in therapeutic programs delivered in outpatient 
settings and, with appropriate measures, in programs delivered in residential 
settings. 
Some authors pointed out  the usefulness of a group cognitive-behavioural 
approach  for  patients  who  were  diagnosed  with  cocaine  abuse  or 
dependence (Tzilos et al., 2009, Sanchez et al., 2011). 
Therefore, the aim of the study was to adapt individual cognitive-behavioural 
therapy  to  a  group  treatment  format  for  patients  with  cocaine  abuse  or 
dependence in order to provide a valid and effective psychotherapeutic group 
treatment for patients with this condition seeking treatment.
6.2. General characteristics of the intervention
The group  CBT carried  out  in  the  present  study is  an  adaptation  of  the 
method validated by Carroll in 1998 for patients with cocaine dependence or 
abuse. 
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The CBT therapeutic approach is based on the collaboration between patient 
and therapist,  who  are both  involved in  the  identification  of  dysfunctional 
ways of thinking and alternative solutions to deal with problematic situations. 
An  essential  technique  is  functional  analysis,  that  allows  to  identify 
determinants of substance use in different relevant domains of patient's life 
(physical,  social,  environmental,  emotional  and  cognitive)  (Carroll,  1998, 
Carroll, 2001). 
An essential  technique is  the  functional  analysis  that  leads to  identify  the 
factors that  contribute to  support   substance use in  different  areas of  the 
patient's life (physical-social, environmental, emotional and cognitive) (Carroll, 
1998). 
Functional analysis requires a careful examination of the circumstances that 
occurred  in  the  periods  before  and  after  each  resumption  of  drug 
consumption or of actual condition relapse (Epstein et al., 2003). 
Through functional analysis the patient detects the situations leading to the 
risk of relapse, then by learning coping skills he or she acquires general and 
specific strategies, , that can immediately be used to reduce and remove the 
use of cocaine. Once acquired, these skills can also be used after the end of 
CBT.
The intervention consists of 12 sessions of 90 minutes duration, to allow all 
participants to share their own experience and participate in role playing. 
In  this  study  sessions  were  delivered  twice  a  week  to  groups  of  4  to  9 
patients. 
The  intervention  started  with  at  least  two  preparatory  meetings,  aimed to 
assess  the  patient’s  motivation  and  the  presence  of  cognitive  functions 
adequate  for  learning  skills  (Carroll,  1998;  Morgan-Lopez  &  Fals-Stewart, 
2007). 
Patients who needed inpatient treatment to stabilize psychiatric comorbidity 
symptoms before starting CBT were  referred to residential  treatment for a 
period of 8 days. In that case the first two CBT sessions were provided during 
hospitalisation and a third one when the patient was discharged. 
After discharge, the CBT sessions were provided at outpatient level (in day-
hospital regimen) twice a week. 
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6.3. Topics
The topics covered in CBT sessions reproduced the "8 topics" of Carroll's 
individual model (1998) adapted to the group format. 
Topics were addressed - in one or more sessions - either in the scheduled 
order or according to the peculiar needs of the group (to allow them to put the 
acquired  skills  into  practice)  or  to  specific  needs  identified  by  therapists 
during the sessions. 
The discussion of each topic was supported by use, both for practice during 
the session and for homeworks, of paper cards to facilitate the understanding 
and conduct of the exercises.
Topic 1: Recognizing and coping with craving, identifying cues and triggers, 
learning to control craving with practice exercises during session and related 
homeworks. 
Topic 2: Shoring up patients motivation and commitment to stop, identifying 
and  coping  with  thoughts  about  cocaine.  It  is  important  to  addressing 
ambivalence of  individual  patients,  so as  not  to  create  tension within  the 
group and/or interfere with the goals achievement. 
Topic 3: Learning and practicing cocaine refusal skills through role play and 
practice exercises.
Topic 4: Understanding Seemingly Irrelevant Decisions (Marlatt & Gordon, 
1985)  and  their  relationships  to  high-risk  situations,  identifying  concrete 
examples  of  Seemingly  Irrelevant  Decisions  and  practicing  safe  decision 
making.
Topic 5:  Developing an all-purpose coping plan to overcome difficulties in 
achieving  and  maintaining  the  abstention  from  cocaine  cocaine.  This 
personal and generic coping plan was based on practical and operational 
items, ordered in timelines. Each patient was given the opportunity to choose 
a significant person to attend this session.
Topic 6  :  Using the  problem solving technique  therapists helped patients to 
identify the best strategy for solving their current problems. Patients were 
asked to practice problem solving skills outside of the sessions. 
Topic 7: Case Management. Reviewing and applying problem-solving skills 
to psychosocial  problems in order to improve a concrete support  plan for  
addressing psychosocial problems.
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Topic  8  :  Providing  guidance on modes  of  transmission  of  HIV and  other 
pathogens responsible for major sexually transmitted diseases. 
6.4. Structure and format of sessions
During the sessions, participants were asked to report their experiences and 
to participate in role playing. Sessions were conducted by a therapist and an 
observer  that   could  support  the  therapist  in  case  of  dysfunctional 
interpersonal  dynamics  or  tension  among  participants  or  between 
participants and the therapist.
1st session
Therapists ensured that patients had understood the general characteristics 
of CBT and filled any gaps by detailing the issues to be addressed during 
treatment. They also outlined the neurobiological basis of addiction, the most 
frequent  clinical  pattern  of  symptoms  and  the  main  acute  and  chronic 
complications related to cocaine use. 
The first session was supported by audiovisual material specifically tailored. 
The use of purely medical language and technical information contributed to 
increasing the interest of the group. 
Sessions 2nd - 11th 
To achieve an effective balance between the theoretical indications on the 
conduct of sessions and the need to save an adequate time for patients' self-
expression, the "20/20/20 rule" proposed by Carroll (1998) for these sessions 
was used and adapted:
During the first 30 minutes, therapists reviewed the patients’ daily self-report  
of craving based on a rating scale of craving for cocaine (Smelson et al., 
1999) and the self-reported cocaine use in the days before the session. For 
each episode of  use,  therapists  spent  several  minutes doing a functional 
analysis.
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Then they asked patients to report the main events that happened to them 
after  the  previous  session,  paying  attention  to  the  way  they  expressed 
themselves  in  order  to  obtain  information  on  their  insight  and  their 
ambivalence with respect to the discontinuation of cocaine use. 
This  phase  was  characterised  by  patients  doing  most  of  the  talking  and 
checking of homework; therapists played the role of facilitators, guiding with 
questions or reflections.
The second half hour was devoted to the introduction and discussion of the 
session  topic  and  skills  that  patients  could  learn  in  the  following  days; 
therapists ascertained the level of understanding of patients.
In  the last  30 minutes,  patients and therapists  agreed on the homework, 
reviewed the plans for the week and anticipated potential high-risk situations 
to be faced before the subsequent session. 
12th session 
The  final  session  was  a  'final  review',  where  the  characteristics  of  the 
objectives of CBT were examined once again. 
Therapists provided their feedback to the group, with particular reference to 
the positive aspects and the progress observed in patients.
Patients were asked to express their level of satisfaction with treatment and 
the remaining concerns about a possible resumption of cocaine use.
7. Materials and methods
7.1. Patients
Participants  were  consecutively  recruited  between  September  2009  and 
March 2012 in an outpatient setting (Addiction Service of Pontedera, Azienda 
USL 5 of Pisa) and in a residential setting (Casa di Cura “Ville di Nozzano”) 
within  the  project  “Assistenza protetta  intensiva  di  persone  dipendenti  da 
cocaina” (Regional Tuscany Resolution n. 6681/2007), attended by 16 local 
Addiction Services  pertaining to nine Tuscany Aziende Sanitarie Locali.
The characteristics of the sample are summarized in Table 1. 
Inclusion  criteria  were  meeting  ICD-9  CM criteria  for  current  (12  months) 
cocaine  abuse  or  dependence  and  age  of  18-65  years.  Patients  with 
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psychiatric disorders in remission and in stable clinical conditions were to be 
enrolled, as well as patients being treated for heroin dependence and those 
with  nicotine  abuse/dependence  or  with  abuse  of  substances  other  than 
cocaine (alcohol, THC). 
Exclusion criteria consisted of meeting ICD-9 CM criteria for bipolar disorder 
or  any  psychotic  disorder  and  being  in  the  acute  phase  of  a  psychiatric 
disorder,  having  a  diagnosis  of  organic  mental  disorder,  having  current 
suicidal ideation or behavior, being on probation or on suspended sentence. 
Written informed consent was obtained from each subject and the study was 
approved by the Ethics Committee of the Azienda Ospedaliero-Universitaria 
of Pisa, Italy.
7.2. Outcomes 
Outcomes were chosen after a systematic review of the scientific literature 
published  by  the  Drugs  and  Alcohol  Group  of  the  Cochrane  Foundation 
(Knapp et al.,  2007; Minozzi et al.,  2008; Amato et al.,  2007; Lima et al., 
2003) and included:
-retention in treatment (i.e. percentage of attendance at planned sessions); 
-cocaine consumption detected with toxicological analytics; 
-craving  for cocaine. 
Craving for cocaine was monitored through a specific form in which patients 
recorded their daily craving on a VAS scale (Smelson et al., 1999; Smelson 
et  al.,2002);  cocaine  use  was  monitored  through  the  detection  of 
benzoylecgonine  in  urine  specimens  with  the  Enzyme  Multiplied 
Immunoassay Technique. (EMIT, Allen & Stiles, 1981). 
Urine samples were collected twice a week- in direct observation of urination 
-  30  minutes  before  the start  of  each session (i.e.  72-96 hours after  the 
previous collection). Samples exceeding the cut-off of 300 ng/ml of urinary 
benzoylecgonine were considered positive.  When biological  samples were 
not released, the data was interpreted as an implicit  acknowledgement of 
cocaine use and was considered as positive. 
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7.3. Statistical analyses
Analyses were carried out to compare treatment outcomes between settings, 
patient  subgroups  (defined  by  psychiatric  comorbidity  or  substance 
abuse/dependence  from  substances  other  than  cocaine)  and between 
patients positive and negative for urinary benzoylecgonine at baseline.
T-test,  analysis  of  variance  and  chi-square  tests  were  used  to  perform 
subgroup comparisons at a significance level of 0.05.
The  daily  trend  of  craving  was  estimated  using  mixed-effect  linear 
regression.  This  procedure  is  appropriate  when  the  response  (such  as 
craving) is gathered over time on the same individuals and when the dataset 
has missing values because some participants fail to provide the response at 
each timepoint.  
The Stata procedure xtmixed  (Stata/SE for Windows, version 12.0, College 
Station, TX) was used to this purpose. All the other analyses were carried 
out using IBM SPSS Statistics, version 20.0. 
8. Results
Study participants were 71 males and 11 females, with a mean age of 37.4 
years (SD 7.2, range 22-52). 
Twenty six met criteria for cocaine abuse and 56 for cocaine dependence, 
and 65.9% for other substance use disorders. Patients with alcohol or other 
substance abuse/dependence were more likely to be treated in residential 
facilities  (69.0%  vs.  58.3%),  however  this  difference  was  not  statistically 
significant (χ²=0.853, df=1, p=0.356).
The proportion with positive urine analyses at baseline was 58.5%.
A large percentage of patients (69.5%) met criteria for psychiatric disorders,  
the most common being bipolar disorder (47.6 %). There was no difference 
between  settings  in  the  proportion  of  patients  with  comorbid  psychiatric 
disorders (77.6% vs. 70.8%, χ²=0.420, df=1, p=0.517).  
The other characteristics of the sample are summarized in Table 1. 
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Outcomes
Compliance with CBT
Of the 24 outpatients, one discontinued prematurely the study at the 2 nd, one 
at the 3rd and one at the 8th visit. Of the 58 residential patients, one dropped 
out at the 2nd visit and 10 between 6th and the 11th visit. Overall, 32.9% of 
patients  completed all  the  12 study sessions and on average attended 9 
sessions, with no statistically significant difference between settings (table 2). 
However,  compared  with  the  residential  setting,  a  higher  retention  in 
treatment was observed in the outpatient setting, where 62.5% of patients 
attended at least 11 study sessions (figure 1).
Compliance with CBT proved to be significantly higher among patients who 
were negative for cocaine metabolites at baseline (table 2). 
Negative urine analyses
At the end of treatment, 41% of participants had negative urine analyses, with 
no significant differences between settings. Patients who were negative at 
baseline for cocaine metabolite were more likely to stay negative at the end of 
treatment (table 2). 
Craving
In the overall sample, craving was on average mild at baseline (mean=30.1), 
with  a  large  variability  among  patients  (SD=31.0).  Figure  2  shows  the 
estimated  daily  craving  over  the  6  weeks  of  CBT treatment  in  the  study 
groups. On average craving decreased daily by -0.419 points in outpatients 
and exhibited a modest  increase in  residential  patients (+0.038 points).  In 
other words, craving decreased by about 3 points per week in outpatients and 
remained substantially stable in residential patients. The daily trend differed 
significantly between settings, suggesting that CBT was more effective among 
outpatients than among residential patients (Z=5.34, p<0.001). 
Of note, a decline in craving was found in patients positive for cocaine at 
baseline but not in those negative at baseline (figure 2) (-0.528 points vs. 
+0.103 points, Z=-6.39, p<0.001).  
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Study subgroups
Table 2 shows the study outcomes in subgroups of patients. About two thirds 
of  outpatients  and  one  third  of  residential  patients  had  negative  urine 
analyses, although the difference between percentages was not significant 
(outpatients: 54.2%, residential patients: 36.2%, χ²=2.256, df=1, p=0.133).
Compliance  with  CBT  sessions  and  the  proportion  with  negative  urine 
analyses did not differ between settings, presence or absence of stabilized 
psychiatric disorders, alcohol use. However, patients with opioid dependence 
(either in remission or not) had a significantly lower percentage of negative 
urine analyses (χ²=7.762, df=2, p=0.021) and were less compliant than those 
who did not use opioids.
While in general study subgroups displayed a downward or stable trend of 
craving over time, a remarkable increase was found in patients with current 
opioid dependence during treatment. Although this result is consistent with 
the poor outcomes observed in these patients, it should be considered with 
caution because of the small number of individuals in this subgroup.
Comparison of craving slopes between patients with and without alcohol use 
and  with  and  without  comorbid  psychiatry  disorders  did  not  reveal  any 
significant differences. 
9. Discussion
We  adapted  the  individual  Cognitive  Behavioural  Therapy  validated  by 
Carroll and colleagues to the group format for patients with cocaine abuse or 
dependence.  The  reason  for  this  choice  was  the  short  duration  of  the 
therapy, the lower cost of the group CBT compared with the individual CBT 
approach, the possibility to deliver this therapy in different settings and to 
adjust the frequency of sessions. Actually, one study showed that this factor 
does not affect the craving and/or the use of cocaine (Covi et al., 2002).
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To  our  knowledge,  this  is  the  largest  study  conducted  on  patients  with 
cocaine abuse or dependence in which group CBT was provided as unique 
or adjunctive treatment.
The group format used in this study is characterised by some differences 
from the intervention in individual form validated by Carrol et coll., for which 
some scientific evidence is already available. (Carroll et al., 1994; Carroll et 
al. , 1998; Carroll et al., 2000; Carroll et al., 2004). Differences include:
- the longer duration of each session (90 min vs. 60 min), according to the 
rule 30/30/30, to allow participants to report their personal experience, bring 
examples and participate in role playing;
-  the  shorter  overall  duration  of  treatment  (6  weeks  vs.  12  weeks)  with 
biweekly sessions; 
-  the presence of  an observer  that  may support  the  therapist  in  case of 
tension  of  disfunctional  dynamics  among group  participants  and  between 
patients and the therapist.  
To the best of our knowledge, the only results available in literature on group 
interventions  that  combine  strategies  of  contingency  management  and 
cognitive-behavioural therapy are related to 19 patients enrolled in an open 
group treatment (Sanchez et al., 2011) or being treated with methadone in 
the long term, with a completion rate of the intervention of 38% (Tzilos et al.,  
2009), associated with the intake of high doses of agonist and toxicological-
analytical baseline negative for benzoylecgonine. 
The present  study was  conducted in  two  settings:  a  residential,  in  which 
patients  began  treatment  during  hospitalisation  and  completed  it  in  day-
hospital regimen, and an outpatient setting. 
In order to foster the effectiveness of treatment, CBT was conducted in small  
groups (4-9 people), taking into account that participation in larger groups 
becomes inhomogeneous, and patients with less motivation tend to passively 
participate in the sessions. In addition, the introduction of participants and the 
acquisition  of  skills  in  small  groups  promotes  a  better  basis  for  sharing 
experiences. 
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Our  results  indicate  significantly  better  outcomes  for  patients  treated  in 
outpatient setting compared to those enrolled for residential treatment, both 
in terms of participation in the 12 CBT sessions and cocaine craving. This 
may be partly explained by a greater motivation of patients enrolled in the 
outpatient  setting  compared  with  those  who  were  referred  to  residential 
treatment. 
In  fact,  only  two  outpatients  discontinued  CBT at  an  early  stage  (8.3%), 
whereas about one fifth dropped out (19.0%) among patients treated in a 
residential regimen at the end of the hospitalisation stage.
Early  discontinuation  in  most  cases  identifies  patients  less  motivated  to 
discontinue substance use (Dutra et al. 2009, Knapp et al., 2009). 
As  a  matter  of  fact,  the  population  of  patients  with  cocaine  dependence 
requiring  treatment  is  heterogeneous  in  terms  of  pattern  of  cocaine 
consumption,  use  of  other  substances,  psychiatric  comorbidities,  type  of 
treatment required (Stulz et al., 2010). 
This poses the challenge of developing and delivering non-pharmacological 
treatments  targeted  to  subgroups  of  patients  with  important  physical 
comorbidities,  particularly  cardiovascular  disease (Aquaro  et  al.,  2011)  - 
associated with the use of other substances. 
Toxicological  analyses  did  not  reveal  statistically  significant  differences 
between  outpatients  and  residential  patients  in  terms  of  detection  of 
benzoilecgnonine  in  urine  specimens,  which  would  indicate  that  the 
residential setting is not prognostically better than the outpatient regimen.
This  observation  is  consistent with  the  original  model of Carroll [16], 
according to which CBT delivered in outpatient settings allows subjects to 
test strategies acquired through the comparison with the context of their daily 
life.
The  reduction  of  craving  is  certainly  a  measure  of  effectiveness  of  the 
intervention.  All participants in the study were then asked to indicate every 
day the maximum value of cocaine craving on special visual-analogue forms 
(VAS, Smelson et al., 1999)
The regular monitoring of craving carried out during the treatment has been a 
valuable aid for the control  of  the clinical  status of  patients,  as well  as a 
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method of assessing the risk of resuming the use of the substance in the 
short term (Ahmadi et al., 2009; Rohosenow et al., 2007).
The temporal trend of craving in the two study settings showed that, while 
craving  remains  essentially  unchanged  in  residential  participants,  it 
undergoes a statistically significant reduction in outpatients, supporting the 
hypothesis that CBT can be offered as a first-line therapeutic intervention for 
outpatient  treatment  of  cocaine  dependence  and  abuse. Moreover,  this 
observation is consistent with the original model of Carroll (1998), according 
to which CBT delivered in outpatient settings allows subjects to test learned 
coping strategies early in their daily life. 
However, some patients would use cocaine even in the absence of craving, 
as an expression of a pattern of automatic behaviour (Canales JJ, 2005; F. 
Weiss, 2010).
Over half of the patients undergoing group CBT (65,9%) shows a comorbidity 
with other conditions associated with the use of substances, in particular with 
alcohol (29,3%%). 
This is in line with what was reported by numerous Authors on the role of 
cocaethylene, a toxicologically-active metabolite produced by condensation 
between  ethanol  and  cocaine,  in  determining  a  reinforcing  action  in  the 
perception of the effects of cocaine and its specific toxicity for organs and 
systems (McCance-Katz et al., 1998; Harris et al., 2003). 
Patients addicted to alcohol report a quantitatively greater use of cocaine and 
the  development  of  more  negative  consequences  (Mengis  et  al.,  2002; 
Flanner  et  al.,  2004);  it  is  a  known  fact  that  the  impact  of  comorbidity 
between pathologies  associated with  alcohol  and cocaine use extends to 
psycho-social areas, including difficulties in the family, and often correlates 
with  a higher  level  of  psychiatric  comorbidity  (Flanner et  al.,  2004; Rash, 
Alessi & Petry, 2008).
However,  our results also show - in line with  the literature (Mengis et  al, 
2002; Crits-Christoph et al., 2007; Carroll et al., 1998) - that comorbidity of 
between cocaine and alcohol  use does not necessarily have a significant 
impact on the outcomes of the treatment. 
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Moreover, compared with patients without opioid addiction, the subgroup of 
patients  with  opioid  addiction  (either  in  remission  or  not)  had  poorer 
outcomes, in terms of compliance or lab-toxicological results (Rowan -Szal et 
al., 2005; Rawson et al., 2002; Rawson et al., 1994), suggesting that group 
CBT may not be suitable for these patients. 
Our results indicate that the large majority (69,5%) of patients met the criteria 
for lifetime psychiatric disorders, mainly bipolar disorder (47,5%).
This  is  consistent  with  evidence  from  the  literature  suggesting  a  specific 
relationship  between  bipolar  disorder  and  psychostimulants  use  disorders 
(Swann, 2010, Ford et al., 2009, Mitchell et al., 2007).
Bipolar disorder and substance-use disorders commonly occur in the same 
individual. In fact, bipolar disorder has a higher prevalence of substance-use 
disorders than any other psychiatric illness. Individuals with  both disorders 
have a more severe course of bipolar disorder, including earlier onset, more 
frequent  episodes,  and more  complications,  including  anxiety-  and stress-
related  disorders, aggressive behavior, legal problems, and suicide. Bipolar 
and  substance-use  disorders  share  common  mechanisms,  including 
impulsivity, poor modulation of motivation and responses to rewarding stimuli, 
and susceptibility to behavioral sensitization (Swann, 2010).
Cocaine use is particularly common in patients with  bipolar disorder.  Both 
cocaine use and bipolar disorder are associated with mood symptoms and 
cognitive impairment (Brown et al., 2007).
The  high  rates  of  milder  affective  symptoms  but  not  mania  observed  in 
patients in cocaine abuse treatment settings suggests the symptoms may in 
many  cases  be  associated  with  the  drug  use.  However,  such  patients 
presenting  in psychiatric settings might be suffering from cyclothymic and 
related  attenuated  bipolar  disorders  (type  II).  Substance  abuse  may  be 
associated with medication non-compliance, more mixed or dysphoric mania 
and  possibly  an  earlier   onset  of  affective  symptoms  and  more 
hospitalizations (Sherwood Brown et al.,  2001).  Several  studies indicate a 
specific relationship between bipolar disorder and stimulant use and abuse; it 
has generally been assumed that cocaine  use represents self-enhancement 
or attempts to optimize one's level of hypomania, cyclothymia or hyperthymia.
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Maremmani and coll.  (2008),  in a study that investigate cocaine abuse by 
bipolar subjects in a group of 1090 treatment-seeking heroin addicts,  suggest 
a  complex  model  linking  cocaine  and  bipolarity:  subthreshold  bipolarity, 
including hyperthymic and cyclothymic temperaments, seems to predispose 
to heroin addiction, but craving for the suppressed hypomania in turn could 
lead to cocaine abuse, which eventually unmasks a frank bipolar disorder - in 
some cases leading  to  mixed state,  severe  mania,  as well  as psychosis 
beyond mania. 
Patients with comorbid bipolar disorder need to be stabilized before starting 
CBT,  because  this  treatment  requires  adequate  cognitive  functioning   to 
identify high-risk situations and learn and practice new skills  (Carroll  et al., 
2008; Lee & Rawson, 2008; Aharonovich et al., 2003, 2006). 
Our  findings  suggest  that  the  participation  in  as  many  as  possible  CBT 
sessions and a modest cocaine use at baseline, as well as a high level of 
cognitive  function (Carroll  et  al.,  2000;  Dackis  et  al.,  2005;  Tzilos  et  al.,  
2009), are positive predictors for the effectiveness of CBT.
However, even a high motivation to change and completion of assignments 
are  predictors  of  increased  retention  in  treatment  and  of  a  significant 
reduction in the use of cocaine. This confirms literature  findings (Carroll et 
al.,  1994;  Carroll  et  al.,  2000;  Epstein  et  al.,  2003;  Carroll  et  al.,  2004;  
Gonzales et al., 2006) for individual CBT, in which more durable effects than 
other types of psycho-therapeutic interventions are reported. 
Our experience also indicates that  the antisocial-personality  disorder  may 
represent an exclusion criterion for the group CBT: the presence of antisocial 
patients, when placed in a treatment group, resulted in problems in managing 
interpersonal  dynamics,  making  the  occurrence  of  transgressions  more 
frequent, especially in patients treated in residential settings (Messina et al., 
2003, Gibbon et al., 2010).
10. Limitation
This study has some limitations related to the small sample size (82 subjects) 
and the lack of a structured follow-up after the end of treatment; therefore, 
information about the ability of group CBT to promote the maintenance of 
refraining from cocaine use after the end of treatment is not available.
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Moreover, the motivation to change and completion/assignment of homework 
was not formally assessed.
11. Conclusion
Our results indicate that group CBT seem to be a promising treatment option 
for patients with cocaine addiction. 
We submit  that CBT should be provided in the outpatient setting as first-
choice  treatment for  subjects  with  cocaine  abuse  or  dependence  highly 
motivated to discontinue the use of drug, or as part of a combined treatment 
strategy  (e.g.  CBT  associated  to  pharmacotherapy)  in  patients  with 
psychiatric  and/or  other  toxicological  comorbidity,  in  order  to  improve  the 
outcome of pharmacological treatments. 
. 
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12. Tables 
Table 1. Characteristics of the study sample by setting (n=82). 
outpatient residential
Mean SD Mean SD
Age 34.6 7.1 38,5 7.0
Gende
r N % N %
Female
                    
3 12.5 8 13,8
Male 21 87.5 50 86,2
marital status
unmarried 19 79.2 32 55,1
married or living with partner 5 20,8 17 29.3
divorced/separate
d 9 12.1
Educational level
Primary school 3 5.2
Secondary or vocational 
school 14 58.3 41 70.7
High school or graduate 10 41.7 14 24.1
Working status
Employed 13 54.1 37 63.8
Unemployed 11 45.9 20 34.4
Retired 1 1.7
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 Table 2. Outcomes by setting, positivity for cocaine metabolite at baseline and comorbidity (n=82). 
N Number  of 
sessions 
attended 
(mean±SD)
t-test Percentage  with 
negative  urine 
analysis*
χ² test
Setting 0.887, p=0.378 2.256, p=0.133
     Outpatient 24 9.7±3.3 54.2
     Residential 58 9.0±3.2 36.2
Cocaine 
     Positive 44 8.6±3.2 3.975, p<0.001 31.8 5.688, p=0.017
     Negative 34 10.9±1.7 58.8
Comorbidity 0.177, p=0.860 0.032, p=0.859
Stabilized 
comorbid 
psychiatric 
disorders
57 9.3±3.4 42.1
No  psychiatric 
disorder
25 9.2±3.0 40.0
Bipolar disorder 1.586, p=0.117 0.139, p=0.710
Yes 39 9.8±3.0 43.6
No 43 8.7±3.4 39.5
Opioid use 3.526, p=0.034 7.762, p=0.021
Yes 6 9.3±3.4 0
In remission 26 7.9±3.5 30.8
No 50 9.9±2.9 52.0
Alcohol use 0.586, p=0.559 0.0019, p=0.981
Yes 24 9.6±3.1 41.7
No 58 9.1±3.3 41.4
*) row percentages
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Figure 1.    Percentage of patients attending the study sessions by setting. 
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Figure 2.    Daily craving over the 6 weeks of CBT treatment  by setting and 
positivity for cocaine metabolite at baseline. Results from mixed-effects linear 
regression. 
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Figure 3.    Daily  craving  over  the   6  weeks  of  CBT
       treatment  in  the study  subgroups. 
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